Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Mar. 31, 2022 | Jun. 30, 2022 | Sep. 30, 2021 | |
Document Information [Line Items] | |||
Entity Central Index Key | 0001165320 | ||
Entity Registrant Name | GB SCIENCES INC | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --03-31 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2022 | ||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Mar. 31, 2022 | ||
Document Transition Report | false | ||
Entity File Number | 000-55462 | ||
Entity Incorporation, State or Country Code | NV | ||
Entity Tax Identification Number | 59-3733133 | ||
Entity Address, Address Line One | 3550 W. Teco Avenue | ||
Entity Address, City or Town | Las Vegas | ||
Entity Address, State or Province | NV | ||
Entity Address, Postal Zip Code | 89118 | ||
City Area Code | 866 | ||
Local Phone Number | 721-0297 | ||
Title of 12(g) Security | Common Stock $.0001 Par Value | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 11,300,000 | ||
Entity Common Stock, Shares Outstanding | 329,204,224 | ||
Auditor Name | Assurance Dimensions, Inc. | ||
Auditor Location | Margate, FL | ||
Auditor Firm ID | 5036 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Mar. 31, 2022 | Mar. 31, 2021 |
Cash and cash equivalents | $ 233,893 | $ 793,040 |
Prepaid expenses and other current assets | 93,933 | 256,251 |
Current assets from discontinued operations | 0 | 2,494,564 |
TOTAL CURRENT ASSETS | 327,826 | 3,543,855 |
Property and equipment, net | 0 | 25,022 |
Intangible assets, net of accumulated amortization of $104,201 and $43,096 at March 31, 2022 and 2021, respectively | 2,222,074 | 1,706,762 |
Long term assets from discontinued operations | 0 | 5,530,415 |
TOTAL ASSETS | 2,549,900 | 10,806,054 |
CURRENT LIABILITIES: | ||
Accounts payable | 1,657,008 | 1,412,459 |
Accrued interest | 384,769 | 493,741 |
Accrued liabilities | 9,627 | 957,946 |
Notes and convertible notes payable, net of unamortized discount of $1,765 and $296,504 at March 31, 2022 and 2021, respectively | 987,565 | 3,594,804 |
Indebtedness to related parties | 0 | 84,913 |
Income tax payable | 896,495 | 761,509 |
Current liabilities from discontinued operations | 0 | 1,293,076 |
TOTAL CURRENT LIABILITIES | 3,935,464 | 8,598,448 |
Convertible notes payable, net of unamortized discount of $99,489 and $154,590 at March 31, 2022 and 2021, respectively | 397,308 | 292,410 |
Long term liabilities from discontinued operations | 0 | 3,389,124 |
TOTAL LIABILITIES | 4,332,772 | 12,279,982 |
Commitments and contingencies (Note 11) | ||
STOCKHOLDERS' EQUITY/(DEFICIT): | ||
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 325,037,557 and 315,340,411 outstanding at March 31, 2022 and 2021, respectively | 32,504 | 31,534 |
Additional paid-in capital | 102,764,746 | 102,380,770 |
Accumulated deficit | (104,580,122) | (103,886,232) |
TOTAL STOCKHOLDERS' EQUITY/(DEFICIT) | (1,782,872) | (1,473,928) |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ 2,549,900 | $ 10,806,054 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - USD ($) | Mar. 31, 2022 | Mar. 31, 2021 |
Intangible assets, accumulated amortization | $ 104,201 | $ 43,096 |
Unamortized discount, current | 1,765 | 296,504 |
Unamortized discount, noncurrent | $ 99,489 | $ 154,590 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 600,000,000 | 600,000,000 |
Common stock, shares issued (in shares) | 325,037,557 | 315,340,411 |
Common stock, shares outstanding (in shares) | 325,037,557 | 315,340,411 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Sales revenue | $ 0 | $ 0 |
Cost of goods sold | 0 | 0 |
Gross profit (loss) | 0 | 0 |
General and administrative expenses | 1,868,734 | 2,001,617 |
LOSS FROM OPERATIONS | (1,868,734) | (2,001,617) |
OTHER INCOME (EXPENSE) | ||
Gain on extinguishment | 22,405 | 467,872 |
Gain on settlement of accounts payable | 0 | 422,414 |
Gain on deconsolidation | 5,206,208 | 0 |
Interest expense | (474,768) | (1,285,460) |
Loss on modification of line of credit | 0 | (650,000) |
Loss on impairment of note receivable | (3,025,000) | 0 |
Debt default penalty | 0 | (286,059) |
Loss on disposal | (15,639) | 0 |
Other income | 9,000 | 0 |
Total other income/(expense) | 1,722,206 | (1,331,233) |
LOSS BEFORE INCOME TAXES | (146,528) | (3,332,850) |
Income tax expense (Note 8) | 0 | 0 |
LOSS FROM CONTINUING OPERATIONS | (146,528) | (3,332,850) |
Net loss from discontinued operations (Note 4) | (384,345) | (392,177) |
NET LOSS | (530,873) | (3,725,027) |
Net loss attributable to common stockholders of GB Sciences, Inc. - basic and diluted | ||
Continuing operations, basic | 146,528 | 3,332,850 |
Discontinued operations, basic | 384,345 | 392,177 |
Net loss | $ (530,873) | $ (3,725,027) |
Net loss per common share – basic and diluted | ||
Continuing operations (in dollars per share) | $ 0 | $ (0.01) |
Discontinued operations (in dollars per share) | 0 | 0 |
Net loss (in dollars per share) | $ 0 | $ (0.01) |
Weighted average common shares outstanding - basic and diluted (in shares) | 317,621,942 | 285,190,729 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Stockholders' Equity/(Deficit) - USD ($) | Compensation Warrant [Member] Common Stock [Member] | Compensation Warrant [Member] Additional Paid-in Capital [Member] | Compensation Warrant [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Mar. 31, 2020 | 275,541,602 | ||||||
Balance at Mar. 31, 2020 | $ 27,554 | $ 97,271,157 | $ (97,387,205) | $ (88,494) | |||
Issuance of stock for debt conversion (in shares) | 4,000,000 | ||||||
Issuance of stock for debt conversion | $ 400 | 159,600 | 160,000 | ||||
Exercise of warrants for stock (in shares) | 35,798,809 | ||||||
Exercise of warrants for stock | $ 3,580 | 964,443 | 968,023 | ||||
Share based compensation expense | 436,349 | 436,349 | |||||
Beneficial conversion feature on notes payable | 543,886 | 543,886 | |||||
Compensation warrants | 231,335 | 231,335 | |||||
Induced Dividend from Warrant Exercises | 2,774,000 | (2,774,000) | |||||
Net loss | (3,725,027) | (3,725,027) | |||||
Exercise of Warrants for Stock, Shares (in shares) | 35,798,809 | ||||||
Exercise of warrants for stock | $ 3,580 | 964,443 | 968,023 | ||||
Issuance of shares upon exercise of compensation warrants | $ 3,580 | 964,443 | 968,023 | ||||
Stock options issued as compensation for drafting and filing patents | 168,000 | ||||||
Balance (in shares) at Mar. 31, 2021 | 315,340,411 | ||||||
Balance at Mar. 31, 2021 | $ 31,534 | 102,380,770 | (103,886,232) | (1,473,928) | |||
Exercise of warrants for stock (in shares) | 7,601,813 | 2,095,333 | |||||
Exercise of warrants for stock | $ 760 | $ 75,308 | $ 76,068 | $ 210 | 56,184 | 56,394 | |
Share based compensation expense | 60,667 | 60,667 | |||||
Induced Dividend from Warrant Exercises | 163,017 | (163,017) | |||||
Net loss | (530,873) | (530,873) | |||||
Exercise of Warrants for Stock, Shares (in shares) | 7,601,813 | 2,095,333 | |||||
Exercise of warrants for stock | $ 760 | 75,308 | 76,068 | $ 210 | 56,184 | 56,394 | |
Issuance of shares upon exercise of compensation warrants | $ 760 | $ 75,308 | $ 76,068 | $ 210 | 56,184 | 56,394 | |
Stock options issued as compensation for drafting and filing patents | 28,800 | 28,800 | |||||
Balance (in shares) at Mar. 31, 2022 | 325,037,557 | ||||||
Balance at Mar. 31, 2022 | $ 32,504 | $ 102,764,746 | $ (104,580,122) | $ (1,782,872) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
OPERATING ACTIVITIES: | ||
Net loss | $ (530,873) | $ (3,725,027) |
Loss from discontinued operations | (384,345) | (392,177) |
Net loss from continuing operations | (146,528) | (3,332,850) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 70,488 | 47,353 |
Stock-based compensation | 60,667 | 436,349 |
Compensation warrants | 0 | 231,335 |
Amortization of debt discount and beneficial conversion feature | 356,340 | 776,122 |
Debt default penalty | 0 | 286,059 |
Loss on modification of line of credit | 0 | 650,000 |
Gain on extinguishment | (22,405) | (467,872) |
Gain on settlement of accounts payable | 0 | (422,414) |
Loss on disposal of assets | 15,639 | 0 |
Loss on impairment of note receivable | 3,025,000 | 0 |
Gain on deconsolidation | (5,206,208) | 0 |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other current assets | 162,318 | (237,475) |
Accounts payable | 821,253 | (248,115) |
Accrued expenses | (948,319) | 166,828 |
Accrued interest | 118,286 | 549,703 |
Indebtedness to related parties | (84,913) | (501,599) |
Net cash used in operating activities of continuing operations | (1,778,382) | (2,066,576) |
Net cash used in operating activities of discontinued operations | (87,772) | (118,644) |
Net cash used in operating activities | (1,866,154) | (2,185,220) |
INVESTING ACTIVITIES: | ||
Proceeds from sale of Nevada Subsidiaries | 1,648,772 | 0 |
Proceeds of note receivable | 0 | 5,051,923 |
Acquisition of intangible assets | (200,000) | (292,675) |
Net cash provided by investing activities of continuing operations | 1,448,772 | 4,759,248 |
Net cash provided by/(used in) investing activities of discontinued operations | 1,567 | (103,729) |
Net cash provided by investing activities | 1,450,339 | 4,655,519 |
FINANCING ACTIVITIES: | ||
Proceeds from warrant exercises | 138,728 | 1,075,396 |
Proceeds from convertible notes payable | 50,000 | 725,000 |
Proceeds from line of credit | 0 | 375,000 |
Principal payment on notes payable | (575,000) | (3,156,014) |
Principal payment on related party note | 0 | (151,923) |
Brokerage fees from warrant exercises and stock issuances | (6,266) | (107,373) |
Fees for issuance of convertible notes | 0 | (74,750) |
Net cash used in financing activities of continuing operations | (392,538) | (1,314,664) |
Net cash used in financing activities of discontinued operations | (103,387) | (161,768) |
Net cash used in financing activities | (495,925) | (1,476,432) |
NET CHANGE IN CASH AND CASH EQUIVALENTS | (911,740) | 993,867 |
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR | 1,145,633 | 151,766 |
CASH AND CASH EQUIVALENTS AT END OF YEAR | 233,893 | 1,145,633 |
Less: cash and cash equivalents classified as discontinued operations | 0 | (352,593) |
CASH AND CASH EQUIVALENTS AT END OF YEAR FROM CONTINUING OPERATIONS | 233,893 | 793,040 |
Cash paid for interest | 0 | 241,014 |
Cash paid for income tax | 0 | 0 |
Noncash investing and financing transactions: | ||
Note receivable from sale of Nevada Subsidiaries | 3,025,000 | 0 |
Extinguishment of debt and accrued interest owed to purchasers of Nevada Subsidiaries and purchasers' affiliates | 2,612,854 | 0 |
Extinguishment of accrued management fees payable to purchaser of Nevada Subsidiaries | 850,000 | 0 |
Accrued liabilities forgiven in connection with Wellcana Note settlement | 0 | 172,500 |
Depreciation capitalized in inventory (discontinued operations) | 349,015 | 532,785 |
Accrued interest capitalized in convertible note principal | 0 | 223,094 |
Patent acquisition costs capitalized in intangible assets | 347,617 | 319,939 |
Stock options issued for preparing capitalized patent applications | 28,800 | 168,000 |
Stock issued upon conversion of notes payable | 0 | 160,000 |
Inducement dividend from warrant exercises | 163,017 | 2,774,000 |
Convertible Notes Payable [Member] | ||
Noncash investing and financing transactions: | ||
Beneficial conversion feature on notes payable | $ 0 | $ 543,886 |
Note 1 - Background and Nature
Note 1 - Background and Nature of Operations | 12 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | Note 1 Business GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) is a phytomedical research and biopharmaceutical drug development company engaged in creating patented formulations of plant-inspired, complex therapeutic mixtures for the prescription drug market that target a variety of medical conditions. The Company is engaged in the research and development of plant-based medicines and plans to produce plant-inspired, complex therapeutic mixtures based on its portfolio of intellectual property. The Company is engaged in the research and development of plant-based medicines, primarily cannabinoid-inspired medicines, with virtual operations in North America and Europe. GBSGB’s assets include a portfolio of intellectual property containing both proprietary cannabinoid-containing formulations and our AI-enabled drug discovery platform, as well as critical research contracts and key supplier arrangements. GBSGB’s intellectual property covers a range of medical conditions and several programs are in the pre-clinical animal stage of development including Parkinson’s disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB’s intellectual property portfolio includes five nine one 35 We were incorporated in the State of Delaware on April 4, 2001, March 28, 2008, On April 4, 2014, December 12, 2016, Effective April 8, 2018, August 15, 2019, 400,000,000 Recent Developments Intellectual Property Portfolio On October 14th, 2020, In Silico Meta-Pharmacopeia Assembly from Non-Western Medical Systems Using Advanced Data Analytic Techniques to Identify and Design Phytotherapeutic Strategies”. GBSGB’s proprietary data analytics tool uses in silico convergence analysis to deconvolve modes of action and predict desirable components of plant-based formulations established in traditional medical practice based on computational consensus analysis across cultures and medical systems. On September 23rd, no January 31, 2018 December 8, 2020, 10,857,107. On April 7th, 2020, May 19, 2020, 10,653,640. On May 12th, 2020, July 14, 2020, 10,709,670. Divestiture of Nevada Cannabis Operations On March 24, 2020, On August 10, 2020, 483 October 23, 2017 ( 5 The closing of the Teco and Nopah sales was contingent upon the successful transfer of the Nevada cultivation and production licenses. On December 14, 2021, December 31, 2021. no As consideration for the membership interests, the Company received cash payments of $1,648,772 (including $400,000 in advance payments received during the nine December 31, 2021), 13 |
Note 2 - Going Concern
Note 2 - Going Concern | 12 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | Note 2 The Company’s consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $104,580,122 at March 31, 2022 March 31, 2022 March 31, 2021 March 31, 2022 March 31, 2021 one Management has been able, thus far, to finance the losses through a public offering, private placements of debt and equity, and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying consolidated financial statements do not may |
Note 3 - Basis of Presentation
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies | 12 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 3 Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. The subsidiaries of the Company are: Continuing Operations: GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC GB Sciences Texas, LLC Discontinued Operations: GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC GB Sciences Nopah, LLC Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, collectibility of notes receivable, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, income taxes payable were reclassified from current liabilities from discontinued operations to income taxes payable from discontinued operations, to reflect that this liability, while related to discontinued operations, remains an obligation of GB Sciences, Inc. and was not December 31, 2021 13 no Discontinued Operations See Note 4 Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value, primarily due to the short-term nature of the instruments. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three March 31, 2022 2021 Indefinite and Definite-Lived Intangible Assets Our indefinite-lived intangible assets primarily represent the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also included the acquisition cost of a cannabis production license with an indefinite life as of March 31, 2021 We amortize our finite-lived intangible assets, which consist of granted patents, over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. We review all of our intangible assets for impairment indicators throughout the year. Impairment testing for indefinite-lived intangible assets is performed at least annually and we perform testing for definite-lived intangible assets whenever impairment indicators are present. If we determine that the fair value is less than the carrying value of these assets during testing, we record impairment losses equal to the difference between the carrying value of the asset and the fair market value of the asset. At March 31, 2022 January 2038 May 2039. March 31, 2022 2021 March 31, 2022 There were 18 United States patent applications that are pending as of March 31, 2022 March 31, 2022 March 31, 2022 Operating Lease Right-of-Use Asset and Liability The Company determines if an arrangement is a lease at inception and had lease agreements for office facilities, equipment, and other space and assets with non-cancelable lease terms which were primarily components of discontinued operations. Certain real estate and property leases, and various other operating leases are measured on the balance sheet with a lease liability and right-of-use asset ("ROU"). ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the New Lease Standard. Lease payments do not Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of twelve not Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3 8 not Long-Lived Assets Property and equipment comprised a significant portion of our total assets from discontinued operations as of March 31, 2021. may March 31. may not Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, Debt with Conversion and Other Options 00 27, “Application of Issue No. 98 5 first 718 Compensation – Stock Compensation The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not Research and Development Costs Research and development costs are expensed as incurred. During the years ended March 31, 2022 2021 Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operated in the State-licensed cannabis industry until the December 31, 2021 13 280E “280E” 280E, no not may not 280E. Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the year. The Company had 118,594,624 and 164,049,941 potentially dilutive common shares at March 31, 2022 2021 not Recent Accounting Pronouncements Standards Recently Adopted In May 2021, No. 2021 04, 2021 04 April 1, 2022. April 1, 2022 not Standards Not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not |
Note 4 - Discontinued Operation
Note 4 - Discontinued Operations | 12 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] | Note 4 Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period, or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The Company has included its subsidiaries GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC in discontinued operations due to the sale of the Company's Nevada Subsidiaries (Note 13 The assets and liabilities associated with discontinued operations included in our consolidated balance sheets as of March 31, 2022 2021 March 31, 2022 March 31, 2021 Continuing Discontinued Nevada Subsidiaries Total Continuing Discontinued Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 233,893 $ - $ 233,893 $ 793,040 $ 352,593 $ 1,145,633 Accounts receivable, net - - - - 400,175 400,175 Inventory, net - - - - 1,689,304 1,689,304 Prepaid and other current assets 93,933 - 93,933 256,251 52,492 308,743 TOTAL CURRENT ASSETS 327,826 - 327,826 1,049,291 2,494,564 3,543,855 Property and equipment, net - - - 25,022 4,876,247 4,901,269 Intangible assets, net 2,222,074 - 2,222,074 1,706,762 571,264 2,278,026 Deposits and other noncurrent assets - - - - 82,904 82,904 TOTAL ASSETS $ 2,549,900 $ - $ 2,549,900 $ 2,781,075 $ 8,024,979 $ 10,806,054 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,657,008 $ - $ 1,657,008 $ 1,412,459 $ 509,477 $ 1,921,936 Accrued interest 384,769 - 384,769 493,741 49,211 542,952 Accrued liabilities 9,627 - 9,627 957,946 105,421 1,063,367 Notes and convertible notes payable, net 987,565 - 987,565 3,594,804 485,000 4,079,804 Indebtedness to related parties - - - 84,913 - 84,913 Income tax payable 896,495 - 896,495 761,509 - 761,509 Finance lease obligations, current - - - - 143,967 143,967 TOTAL CURRENT LIABILITIES 3,935,464 - 3,935,464 7,305,372 1,293,076 8,598,448 Convertible notes payable, net 397,308 - 397,308 292,410 - 292,410 Finance lease obligations, long term - - - - 3,389,124 3,389,124 TOTAL LIABILITIES $ 4,332,772 $ - $ 4,332,772 $ 7,597,782 $ 4,682,200 $ 12,279,982 The revenues and expenses associated with discontinued operations included in our consolidated statements of operations for the years ended March 31, 2022 2021 For the Year Ended March 31, For the Year Ended March 31, 2022 2021 Continuing Discontinued - Nevada Total Continuing Discontinued - Nevada Total Sales revenue $ - $ 3,369,812 $ 3,369,812 $ - $ 4,110,456 $ 4,110,456 Cost of goods sold - (3,072,622 ) (3,072,622 ) - (3,506,722 ) (3,506,722 ) Gross profit (loss) - 297,190 297,190 - 603,734 603,734 General and administrative expenses 1,868,734 264,515 2,133,249 2,001,617 276,986 2,278,603 LOSS FROM OPERATIONS (1,868,734 ) 32,675 (1,836,059 ) (2,001,617 ) 326,748 (1,674,869 ) OTHER INCOME/(EXPENSE) Gain on extinguishment 22,405 - 22,405 467,872 - 467,872 Gain on settlement of accounts payable - - - 422,414 54,958 477,372 Gain on deconsolidation 5,206,208 - 5,206,208 - - - Interest expense (474,768 ) (302,923 ) (777,691 ) (1,285,460 ) (486,481 ) (1,771,941 ) Loss on modification of line of credit - - - (650,000 ) - (650,000 ) Loss on impairment of note receivable (3,025,000 ) - (3,025,000 ) - - - Debt default penalty - - - (286,059 ) - (286,059 ) Loss on disposal (15,639 ) - (15,639 ) - - - Other income 9,000 20,889 29,889 - (118,875 ) (118,875 ) TOTAL OTHER INCOME/(EXPENSE) 1,722,206 (282,034 ) 1,440,172 (1,331,233 ) (550,398 ) (1,881,631 ) NET LOSS BEFORE INCOME TAXES (146,528 ) (249,359 ) (395,887 ) (3,332,850 ) (223,650 ) (3,556,500 ) Income tax expense - (134,986 ) (134,986 ) - (168,527 ) (168,527 ) NET LOSS $ (146,528 ) $ (384,345 ) $ (530,873 ) $ (3,332,850 ) $ (392,177 ) $ (3,725,027 ) Discontinued Operations - Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections. There were no accounts receivable at March 31, 2022 13 March 31, 2021. Discontinued Operations - Inventory We value inventory at the lower of the actual cost of our inventory, as determined using the first first Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress consisted of live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, and extracts in bulk and packaged forms. There is no remaining inventory on the Company's consolidated balance sheet as of March 31, 2022, 13 March 31, 2021. March 31, 2022 March 31, 2021 Inventory (discontinued operations) Raw materials $ - $ 86,076 Work in progress - 743,844 Finished goods - 866,195 Subtotal - 1,696,115 Allowance to reduce inventory to NRV - (6,811 ) Total inventory (discontinued operations) $ - $ 1,689,304 Discontinued Operations - Deposits and Noncurrent Assets Deposits and noncurrent assets from discontinued operations were $82,904 at March 31, 2021. March 31, 2022, March 31, 2021. Discontinued Operations - Leases The Company evaluates all finance and operating leases, and they are measured on the balance sheet with a lease liability and right-of-use asset (“ROU”) at inception. ROU assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not The Company's only remaining lease commitment was a finance lease for the Nevada Subsidiaries, which is classified as discontinued operations in the Company's consolidated balance sheet at March 31, 2021. December 31, 2025 December 31, 2030. Finance leases are included in property and equipment (long term assets from discontinued operations), finance lease obligations, short term (current liabilities from discontinued operations), and finance lease obligations, long term (long term liabilities from discontinued operations), on the balance sheet as of March 31, 2021. The right-of-use asset and lease liability were deconsolidated at December 31, 2021 March 31, 2022 2021 March 31, Lease costs (discontinued operations) Classification on the Statements of Operations 2022 2021 Discontinued operations: Finance leases - amortization of ROU assets Loss from discontinued operations $ 116,024 $ 154,699 Finance leases - interest on lease liabilities Loss from discontinued operations 301,796 414,993 Operating leases Loss from discontinued operations - 3,243 Total lease cost, discontinued operations $ 417,820 $ 572,935 Discontinued Operations - 8% Line of Credit dated November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019 13 not December 29, 2020, no November 30, 2020. December 31, 2021 March 31, 2021 |
Note 5 - Notes Payable and Line
Note 5 - Notes Payable and Line of Credit | 12 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | Note 5 0% October 23, 2017 On October 23, 2017, one three January 1, 2018. On August 10, 2020, December 31, 2021 December 14, 2021 13 On March 4, 2022, We evaluated the modification under the guidance in ASC 470 50 10% The Company made a $75,000 payment pursuant to the terms of the modification on March 4, 2022. March 31, 2022 8% July 24, 2020 On July 24, 2020, "July 24 may 8% February 28, 2019. July 24 3 July 24 On December 29, 2020, three $325,000 July 24 July 24 one No November 30, 2020. not July 24 March 31, 2021. December 31, 2021, $325,000 March 31, 2021, December 31, 2021, no 13 Summary of Notes Payable As of March 31, 2022 As of March 31, 2022 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (as amended), current portion (Note 5) $ 54,330 $ - $ 54,330 6% Convertible promissory notes payable (Note 6) 560,000 - 560,000 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 - 325,000 6% Convertible note payable due July 1, 2022 (Note 6) 50,000 (1,765 ) 48,235 Total short-term notes and convertible notes payable $ 989,330 $ (1,765 ) $ 987,565 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (26,254 ) $ 170,746 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (73,235 ) 176,765 0% Note Payable dated October 23, 2017 (as amended), long term portion (Note 5) 49,797 - 49,797 Total long term convertible notes payable classified as continuing operations $ 496,797 $ (99,489 ) $ 397,308 As of March 31, 2021 As of March 31, 2021 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 6) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 (296,504 ) 28,496 Total short-term notes and convertible notes payable 4,376,308 (296,504 ) 4,079,804 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 3,891,308 $ (296,504 ) $ 3,594,804 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (40,561 ) $ 156,439 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (114,029 ) 135,971 Total long term convertible notes payable classified as continuing operations $ 447,000 $ (154,590 ) $ 292,410 |
Note 6 - Convertible Notes
Note 6 - Convertible Notes | 12 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Convertible Debt [Text Block] | Note 6 March 2017 July 2017 In March 2017, third three March 2017 May 2017, three three In July 2017, third three July 2017 December 2017, three three All notes from the March July 2017 March 31, 2022 $197,000 three September 30, 2023. 10% March 31, 2022 $197,000 March 31, 2022 Three convertible notes totaling $1,060,000 held by the same investor are past maturity and are currently in default. On January 20, 2022, one three not March 31, 2022 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, August 28, 2020, On December 29, 2020, November 30, 2020. December 31, 2021. Upon close of the Teco sale on December 31, 2021, 13 8% April 23, 2019 On April 23, 2019, April 22, 2020. During the year ended March 31, 2020, October 30, 2019, November 18, 2019, On April 22, 2020, 10% March 31, 2021 On May 20, 2020, July 14, 2020, On November 20, 2020, December 8, 2020. December 8, 2020, December 9, 2020, not December 16, 2020, December 18, 2020, no December 2020 $625,000 6% On December 18, 2020, 19 three January 31, 2021 July 1, 2022, December 2023. March 31, 2022, At March 31, 2022 March 31, 2022 |
Note 7 - Property and Equipment
Note 7 - Property and Equipment | 12 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | Note 7 Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of the asset or, in the case of leasehold improvements amortized over the lesser of the useful life of the asset or the underlying lease term. We recorded depreciation expense of $25,775 and $34,654 on a consolidated basis for the years ended year ended March 31, 2022 2021 March 31, 2022 2021 March 31, 2022, no 13 |
Note 8 - Income Taxes
Note 8 - Income Taxes | 12 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | Note 8 The Company files income tax returns in the U.S. federal jurisdiction. The Company operates in the state of Nevada, which does not The Company’s effective tax rate was 1.8% and-3.6% for the years ended March 31, 2022 2021 Income tax expense was $134,986 for the year ended March 31, 2022 March 31, 2018 March 31, 2021 March 31, 2022 March 31, 2021 March 31, 2018 March 31, 2021 March 31, 2022 2021 Because the Company operates in the State-licensed cannabis industry, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. At March 31, 2022 2021 2025 2039. March 31, 2019 no may 50% The provision for income taxes included in discontinued operations is different than would result from applying the U.S. statutory rate to profit before taxes for the reasons set forth in the following reconciliation: 2022 2021 Tax expense/(benefit) computed at U.S. statutory rates $ 691,042 $ (697,040 ) Increases (decreases) in taxes resulting from: IRC Section 280E 132,063 173,045 Other permanent items 5,526 14,407 Change in valuation allowance 579,861 26,720 Adjustments to valuation of deferred tax assets (1,408,492 ) 603,319 Tax return true-up 58,277 - Total provision for income taxes 58,277 120,451 Penalties and interest on prior year tax liabilities 76,709 48,076 Total income tax expense $ 134,986 $ 168,527 The tax effects of the primary temporary differences giving rise to the Company’s deferred tax assets and liabilities are as follows for the year ended March 31, 2022 2021 2022 2021 Deferred tax assets: Stock based compensation $ 3,144,084 $ 3,131,344 Net operating loss carryforward 10,816,588 10,460,788 Impairment of long-lived assets - 975,461 Depreciation and Amortization expense (1,369 ) (458,938 ) Other temporary items (209,714 ) 220,795 Total deferred tax assets 13,749,589 14,329,450 Less valuation allowance (13,749,589 ) (14,329,450 ) Net deferred tax asset $ - $ - Deferred tax assets are evaluated by considering historical levels of income, estimates of future taxable income and the impact of tax planning strategies. The Company continues to evaluate its deferred tax asset valuation allowance on a quarterly basis. The Company concluded that, as of March 31, 2022 not not The Company believes that the tax positions taken in its tax returns would be sustained upon examination by taxing authorities. The Company files income tax returns in the U.S. federal jurisdiction and other required state jurisdictions. The Company's periodic tax returns filed in 2019 |
Note 9 - Capital Transactions
Note 9 - Capital Transactions | 12 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | Note 9 Year Ended March 31, 2022 On April 1, 2020, $.05 July 18, 2021, September 30, 2021 one three March 31, 2022, On March 1, 2022, During the year ended March 31, 2022, one ten six During the year ended March 31, 2022, March 31, 2022. Year Ended March 31, 2021 On April 1, 2020, $0.03 $.05 March 31, 2021, During the year ended March 31, 2021, one ten During the year ended March 31, 2021, three three 6 On November 16, 2020, November 16, 2025, June 1, 2023. On December 7, 2020, ten On December 15, 2020, ten one third one third one one third two March 31, 2021. March 31, 2021. On December 15, 2020, On January 2, 2021, January 2, 2024. December 11, 2020 October 1, 2023, During the quarter ended March 31, 2021, 6 On February 8, 2021, December 2019 three Warrants Outstanding Presented below is a summary of the Company’s warrant activity, exclusive of warrants held by employees (Note 10 March 31, 2022 2021 Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2020 84,538,161 Warrants issued 43,493,809 $0.10 Warrants exercised (35,798,809) 0.03000.03535 Warrants expired/cancelled (6,390,125) 0.6000.9090 Outstanding at March 31, 2021 85,843,036 Warrants issued 2,095,333 $0.10 Warrants exercised (9,697,146) $0.01- $0.03 Warrants expired/cancelled (3,116,550) $0.60 Outstanding at March 31, 2022 75,124,673 |
Note 10 - Employee Benefit Plan
Note 10 - Employee Benefit Plan | 12 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Compensation and Employee Benefit Plans [Text Block] | Note 10 Share-Based Employee Compensation On February 6, 2008, 2007 “2007 2007 may 2014 June 30, 2015, 8 April 6, 2018, 2014 2018 October 25, 2018, 8 2018 On September 17, 2021, 2021 "2021 8 2021 2021 March 31, 2022 Compensation Expense For the years ended March 31, 2022 2021 March 31, 2022 Fair Value The closing price of the Company's stock on the date of grant is used as the fair value for issuances of restricted stock. The fair value of stock options granted is estimated as of the grant date using the Black-Scholes option pricing model. The following range of assumptions in the Black-Scholes option pricing model was used to determine fair value: Year Ended March 31, 2022 March 31, 2021 Weighted-average volatility 131 % 127 % Expected term (in years) 10 % 10 Risk-free interest rate 1.42 % 0.93 % Expected volatilities used for award valuation are based on historical volatility of the Company's common stock. The risk-free interest rate for periods equal to the expected term of an award is based on Federal Reserve yields for U.S. Treasury securities. Stock Options A summary of employee option activity, including warrants issued to employees, as of March 31, 2022 2021 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Employee options and warrants Options Price $ Life (years) Value ($) Outstanding at March 31, 2020 10,983,334 $ 0.28 6.02 $ - Granted 6,750,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2021 17,733,334 $ 0.11 6.80 $ 172,000 Granted - Exercised - Forfeited - Outstanding at March 31, 2022 17,733,334 $ 0.11 5.80 $ - Fully vested and expected to vest at March 31, 2022 17,733,334 $ 0.11 Exercisable at March 31, 2022 15,566,668 $ 0.12 The table below sets forth nonemployee option activity for the years ended March 31, 2022 2021 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Nonemployee options Options Price $ Life (years) Value ($) Outstanding at March 31, 2020 2,383,000 $ 0.27 6.75 $ - Granted 3,500,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2021 5,883,000 $ 0.14 8.11 $ - Granted 600,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2022 6,483,000 $ 0.13 7.31 $ - Fully vested and expected to vest at March 31, 2022 6,483,000 $ 0.13 Exercisable at March 31, 2022 6,483,000 $ 0.13 Restricted stock awards No restricted stock awards were granted during the years ended March 31, 2022 2021 |
Note 11 - Commitments and Conti
Note 11 - Commitments and Contingencies | 12 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | Note 11 On April 11, 2022, May 2020. may On April 22, 2020, May 20, 2020, July 14, 2020, December 16, 2020 6 On April 22, 2020, September 17, 2020, From time to time, the Company may not |
Note 12 - Related Party Transac
Note 12 - Related Party Transactions | 12 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 12 During the year ended March 31, 2022 March 31, 2022 On September 1, 2019, 9 January 2, 2021, On November 16, 2020, March 31, 2021. In connection with the sale of membership interest in GB Sciences Louisiana, LLC, the Company issued a note payable in the amount of $151,923 to John Davis, the Company's former General Counsel and President of GB Sciences Louisiana, LLC, for unpaid compensation and bonuses. The note matured upon receipt of the first August 4, 2020. |
Note 13 - Sale of Membership In
Note 13 - Sale of Membership Interests in Nevada Subsidiaries | 12 Months Ended |
Mar. 31, 2022 | |
Nevada Subsidiaries [Member] | |
Notes to Financial Statements | |
Noncontrolling Interest Disclosure [Text Block] | Note 13 On March 24, 2020, On August 10, 2020, 483 October 23, 2017 5 The closing of the Teco and Nopah sales was contingent upon the successful transfer of the Nevada cultivation and production licenses. On December 14, 2021, December 31, 2021. As consideration for the membership interests, the Company received cash payments of $1,648,772 (including $400,000 in advance payments received during the nine December 31, 2021), 5 6 As the result of sale of the Nevada Subsidiaries, the Company recorded a gain on deconsolidation of $5,206,208 on December 31, 2021, December 31, 2021 Cash payments received, including advancements of $400,000 $ 1,648,772 8% Note Receivable due December 31, 2024 3,025,000 Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates 2,612,854 Extinguishment of accrued management fees due to purchaser 850,000 Total consideration 8,136,626 Carrying amount of assets 7,130,159 Carrying amount of liabilities (4,199,741 ) Net assets deconsolidated 2,930,418 GAIN ON DECONSOLIDATION $ 5,206,208 As the result of sale, the income, assets, and cash flows of GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC have been reclassified as discontinued operations for all periods presented in the Company's consolidated financial statements prior to the sale. Note Receivable from Sale of Teco Subsidiaries The $3,025,000 note receivable from the sale of the Teco Subsidiaries is payable as quarterly, interest only payments of $60,500 for the first March 31, 2023, December 31, 2024. The note contains a provision that allows payments of principal and interest due prior to the maturity date to be postponed to the next quarterly payment date if cash flow from the operations of the facility is insufficient to cover the amount of the payment. Several days prior to the first April 1, 2022, April 1, 2022 July 1, 2022 |
Note 14 - Concentrations
Note 14 - Concentrations | 12 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | Note 14 We held no cash deposits in excess of FDIC limits as of March 31, 2022 March 31, 2021 March 31, 2022 December 31, 2021 13 |
Note 15 - Subsequent Events
Note 15 - Subsequent Events | 12 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 15 May 9, 2022 five one five |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. The subsidiaries of the Company are: Continuing Operations: GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC GB Sciences Texas, LLC Discontinued Operations: GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC GB Sciences Nopah, LLC Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, collectibility of notes receivable, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may |
Reclassification, Comparability Adjustment [Policy Text Block] | Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, income taxes payable were reclassified from current liabilities from discontinued operations to income taxes payable from discontinued operations, to reflect that this liability, while related to discontinued operations, remains an obligation of GB Sciences, Inc. and was not December 31, 2021 13 no |
Discontinued Operations, Policy [Policy Text Block] | Discontinued Operations See Note 4 |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value, primarily due to the short-term nature of the instruments. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three March 31, 2022 2021 |
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] | Indefinite and Definite-Lived Intangible Assets Our indefinite-lived intangible assets primarily represent the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also included the acquisition cost of a cannabis production license with an indefinite life as of March 31, 2021 We amortize our finite-lived intangible assets, which consist of granted patents, over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. We review all of our intangible assets for impairment indicators throughout the year. Impairment testing for indefinite-lived intangible assets is performed at least annually and we perform testing for definite-lived intangible assets whenever impairment indicators are present. If we determine that the fair value is less than the carrying value of these assets during testing, we record impairment losses equal to the difference between the carrying value of the asset and the fair market value of the asset. At March 31, 2022 January 2038 May 2039. March 31, 2022 2021 March 31, 2022 There were 18 United States patent applications that are pending as of March 31, 2022 March 31, 2022 March 31, 2022 |
Lessee, Leases [Policy Text Block] | Operating Lease Right-of-Use Asset and Liability The Company determines if an arrangement is a lease at inception and had lease agreements for office facilities, equipment, and other space and assets with non-cancelable lease terms which were primarily components of discontinued operations. Certain real estate and property leases, and various other operating leases are measured on the balance sheet with a lease liability and right-of-use asset ("ROU"). ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the New Lease Standard. Lease payments do not Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of twelve not |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3 8 not |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Long-Lived Assets Property and equipment comprised a significant portion of our total assets from discontinued operations as of March 31, 2021. may March 31. may not |
Debt, Policy [Policy Text Block] | Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, Debt with Conversion and Other Options 00 27, “Application of Issue No. 98 5 first 718 Compensation – Stock Compensation The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Costs Research and development costs are expensed as incurred. During the years ended March 31, 2022 2021 |
Share-Based Payment Arrangement [Policy Text Block] | Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operated in the State-licensed cannabis industry until the December 31, 2021 13 280E “280E” 280E, no not may not 280E. |
Earnings Per Share, Policy [Policy Text Block] | Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the year. The Company had 118,594,624 and 164,049,941 potentially dilutive common shares at March 31, 2022 2021 not |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements Standards Recently Adopted In May 2021, No. 2021 04, 2021 04 April 1, 2022. April 1, 2022 not Standards Not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not |
Note 4 - Discontinued Operati_2
Note 4 - Discontinued Operations (Tables) | 12 Months Ended |
Mar. 31, 2022 | |
Notes Tables | |
Disposal Groups, Including Discontinued Operations [Table Text Block] | March 31, 2022 March 31, 2021 Continuing Discontinued Nevada Subsidiaries Total Continuing Discontinued Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 233,893 $ - $ 233,893 $ 793,040 $ 352,593 $ 1,145,633 Accounts receivable, net - - - - 400,175 400,175 Inventory, net - - - - 1,689,304 1,689,304 Prepaid and other current assets 93,933 - 93,933 256,251 52,492 308,743 TOTAL CURRENT ASSETS 327,826 - 327,826 1,049,291 2,494,564 3,543,855 Property and equipment, net - - - 25,022 4,876,247 4,901,269 Intangible assets, net 2,222,074 - 2,222,074 1,706,762 571,264 2,278,026 Deposits and other noncurrent assets - - - - 82,904 82,904 TOTAL ASSETS $ 2,549,900 $ - $ 2,549,900 $ 2,781,075 $ 8,024,979 $ 10,806,054 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,657,008 $ - $ 1,657,008 $ 1,412,459 $ 509,477 $ 1,921,936 Accrued interest 384,769 - 384,769 493,741 49,211 542,952 Accrued liabilities 9,627 - 9,627 957,946 105,421 1,063,367 Notes and convertible notes payable, net 987,565 - 987,565 3,594,804 485,000 4,079,804 Indebtedness to related parties - - - 84,913 - 84,913 Income tax payable 896,495 - 896,495 761,509 - 761,509 Finance lease obligations, current - - - - 143,967 143,967 TOTAL CURRENT LIABILITIES 3,935,464 - 3,935,464 7,305,372 1,293,076 8,598,448 Convertible notes payable, net 397,308 - 397,308 292,410 - 292,410 Finance lease obligations, long term - - - - 3,389,124 3,389,124 TOTAL LIABILITIES $ 4,332,772 $ - $ 4,332,772 $ 7,597,782 $ 4,682,200 $ 12,279,982 For the Year Ended March 31, For the Year Ended March 31, 2022 2021 Continuing Discontinued - Nevada Total Continuing Discontinued - Nevada Total Sales revenue $ - $ 3,369,812 $ 3,369,812 $ - $ 4,110,456 $ 4,110,456 Cost of goods sold - (3,072,622 ) (3,072,622 ) - (3,506,722 ) (3,506,722 ) Gross profit (loss) - 297,190 297,190 - 603,734 603,734 General and administrative expenses 1,868,734 264,515 2,133,249 2,001,617 276,986 2,278,603 LOSS FROM OPERATIONS (1,868,734 ) 32,675 (1,836,059 ) (2,001,617 ) 326,748 (1,674,869 ) OTHER INCOME/(EXPENSE) Gain on extinguishment 22,405 - 22,405 467,872 - 467,872 Gain on settlement of accounts payable - - - 422,414 54,958 477,372 Gain on deconsolidation 5,206,208 - 5,206,208 - - - Interest expense (474,768 ) (302,923 ) (777,691 ) (1,285,460 ) (486,481 ) (1,771,941 ) Loss on modification of line of credit - - - (650,000 ) - (650,000 ) Loss on impairment of note receivable (3,025,000 ) - (3,025,000 ) - - - Debt default penalty - - - (286,059 ) - (286,059 ) Loss on disposal (15,639 ) - (15,639 ) - - - Other income 9,000 20,889 29,889 - (118,875 ) (118,875 ) TOTAL OTHER INCOME/(EXPENSE) 1,722,206 (282,034 ) 1,440,172 (1,331,233 ) (550,398 ) (1,881,631 ) NET LOSS BEFORE INCOME TAXES (146,528 ) (249,359 ) (395,887 ) (3,332,850 ) (223,650 ) (3,556,500 ) Income tax expense - (134,986 ) (134,986 ) - (168,527 ) (168,527 ) NET LOSS $ (146,528 ) $ (384,345 ) $ (530,873 ) $ (3,332,850 ) $ (392,177 ) $ (3,725,027 ) |
Lease, Cost [Table Text Block] | March 31, Lease costs (discontinued operations) Classification on the Statements of Operations 2022 2021 Discontinued operations: Finance leases - amortization of ROU assets Loss from discontinued operations $ 116,024 $ 154,699 Finance leases - interest on lease liabilities Loss from discontinued operations 301,796 414,993 Operating leases Loss from discontinued operations - 3,243 Total lease cost, discontinued operations $ 417,820 $ 572,935 |
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | March 31, 2022 March 31, 2021 Inventory (discontinued operations) Raw materials $ - $ 86,076 Work in progress - 743,844 Finished goods - 866,195 Subtotal - 1,696,115 Allowance to reduce inventory to NRV - (6,811 ) Total inventory (discontinued operations) $ - $ 1,689,304 |
Note 5 - Notes Payable and Li_2
Note 5 - Notes Payable and Line of Credit (Tables) | 12 Months Ended |
Mar. 31, 2022 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | As of March 31, 2022 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (as amended), current portion (Note 5) $ 54,330 $ - $ 54,330 6% Convertible promissory notes payable (Note 6) 560,000 - 560,000 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 - 325,000 6% Convertible note payable due July 1, 2022 (Note 6) 50,000 (1,765 ) 48,235 Total short-term notes and convertible notes payable $ 989,330 $ (1,765 ) $ 987,565 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (26,254 ) $ 170,746 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (73,235 ) 176,765 0% Note Payable dated October 23, 2017 (as amended), long term portion (Note 5) 49,797 - 49,797 Total long term convertible notes payable classified as continuing operations $ 496,797 $ (99,489 ) $ 397,308 As of March 31, 2021 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 6) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 (296,504 ) 28,496 Total short-term notes and convertible notes payable 4,376,308 (296,504 ) 4,079,804 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 3,891,308 $ (296,504 ) $ 3,594,804 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (40,561 ) $ 156,439 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (114,029 ) 135,971 Total long term convertible notes payable classified as continuing operations $ 447,000 $ (154,590 ) $ 292,410 |
Note 8 - Income Taxes (Tables)
Note 8 - Income Taxes (Tables) | 12 Months Ended |
Mar. 31, 2022 | |
Notes Tables | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 2022 2021 Tax expense/(benefit) computed at U.S. statutory rates $ 691,042 $ (697,040 ) Increases (decreases) in taxes resulting from: IRC Section 280E 132,063 173,045 Other permanent items 5,526 14,407 Change in valuation allowance 579,861 26,720 Adjustments to valuation of deferred tax assets (1,408,492 ) 603,319 Tax return true-up 58,277 - Total provision for income taxes 58,277 120,451 Penalties and interest on prior year tax liabilities 76,709 48,076 Total income tax expense $ 134,986 $ 168,527 |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | 2022 2021 Deferred tax assets: Stock based compensation $ 3,144,084 $ 3,131,344 Net operating loss carryforward 10,816,588 10,460,788 Impairment of long-lived assets - 975,461 Depreciation and Amortization expense (1,369 ) (458,938 ) Other temporary items (209,714 ) 220,795 Total deferred tax assets 13,749,589 14,329,450 Less valuation allowance (13,749,589 ) (14,329,450 ) Net deferred tax asset $ - $ - |
Note 9 - Capital Transactions (
Note 9 - Capital Transactions (Tables) | 12 Months Ended |
Mar. 31, 2022 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2020 84,538,161 Warrants issued 43,493,809 $0.10 Warrants exercised (35,798,809) 0.03000.03535 Warrants expired/cancelled (6,390,125) 0.6000.9090 Outstanding at March 31, 2021 85,843,036 Warrants issued 2,095,333 $0.10 Warrants exercised (9,697,146) $0.01- $0.03 Warrants expired/cancelled (3,116,550) $0.60 Outstanding at March 31, 2022 75,124,673 |
Note 10 - Employee Benefit Pl_2
Note 10 - Employee Benefit Plan (Tables) | 12 Months Ended |
Mar. 31, 2022 | |
Notes Tables | |
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Year Ended March 31, 2022 March 31, 2021 Weighted-average volatility 131 % 127 % Expected term (in years) 10 % 10 Risk-free interest rate 1.42 % 0.93 % |
Schedule of Stock Options Roll Forward [Table Text Block] | Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Employee options and warrants Options Price $ Life (years) Value ($) Outstanding at March 31, 2020 10,983,334 $ 0.28 6.02 $ - Granted 6,750,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2021 17,733,334 $ 0.11 6.80 $ 172,000 Granted - Exercised - Forfeited - Outstanding at March 31, 2022 17,733,334 $ 0.11 5.80 $ - Fully vested and expected to vest at March 31, 2022 17,733,334 $ 0.11 Exercisable at March 31, 2022 15,566,668 $ 0.12 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Nonemployee options Options Price $ Life (years) Value ($) Outstanding at March 31, 2020 2,383,000 $ 0.27 6.75 $ - Granted 3,500,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2021 5,883,000 $ 0.14 8.11 $ - Granted 600,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2022 6,483,000 $ 0.13 7.31 $ - Fully vested and expected to vest at March 31, 2022 6,483,000 $ 0.13 Exercisable at March 31, 2022 6,483,000 $ 0.13 |
Note 13 - Sale of Membership _2
Note 13 - Sale of Membership Interests in Nevada Subsidiaries (Tables) | 12 Months Ended |
Mar. 31, 2022 | |
Notes Tables | |
Schedule of Deconsolidation [Table Text Block] | December 31, 2021 Cash payments received, including advancements of $400,000 $ 1,648,772 8% Note Receivable due December 31, 2024 3,025,000 Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates 2,612,854 Extinguishment of accrued management fees due to purchaser 850,000 Total consideration 8,136,626 Carrying amount of assets 7,130,159 Carrying amount of liabilities (4,199,741 ) Net assets deconsolidated 2,930,418 GAIN ON DECONSOLIDATION $ 5,206,208 |
Note 1 - Background and Natur_2
Note 1 - Background and Nature of Operations (Details Textual) - USD ($) | 9 Months Ended | 12 Months Ended | |||||||||||
Dec. 31, 2021 | Dec. 14, 2021 | Aug. 10, 2020 | Mar. 24, 2020 | Nov. 27, 2019 | Oct. 23, 2017 | Dec. 31, 2021 | Dec. 31, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | Aug. 15, 2019 | Apr. 08, 2018 | Mar. 31, 2018 | |
Common Stock, Shares Authorized (in shares) | 600,000,000 | 600,000,000 | 600,000,000 | 400,000,000 | 250,000,000 | ||||||||
Notes Reduction | $ 2,612,854 | $ 0 | |||||||||||
Proceeds from Divestiture of Interest in Consolidated Subsidiaries | 1,648,772 | $ 0 | |||||||||||
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | |||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 0% | 0% | |||||||||||
Receivable with Imputed Interest, Effective Yield (Interest Rate) | 20.30% | ||||||||||||
GB Sciences Nopah, LLC [Member] | |||||||||||||
Sale of Stock, Percentage of Ownership | 100% | ||||||||||||
Sale of Interest, Percentage of Ownership | 100% | ||||||||||||
Noncash or Part Noncash Divestiture, Amount of Consideration Received | $ 312,315 | ||||||||||||
Nevada Subsidiaries [Member] | |||||||||||||
Sale of Stock, Percentage of Ownership | 100% | ||||||||||||
Teco Subsidiaries [Member] | |||||||||||||
Sale of Stock, Consideration Received on Transaction | $ 8,000,000 | ||||||||||||
Notes Receivable, Interest Rate | 8% | ||||||||||||
GB Sciences Nopah, LLC [Member] | |||||||||||||
Notes Reduction | 237,668 | ||||||||||||
Extinguishment of Debt, Amount | $ 3,462,854 | $ 3,462,854 | |||||||||||
Sale of Stock, Percentage of Ownership before Transaction | 100% | ||||||||||||
Proceeds from Divestiture of Interest in Consolidated Subsidiaries | 1,648,772 | $ 1,648,772 | |||||||||||
Proceeds From Divestiture of Business, Advances Received | $ 400,000 | 400,000 | 400,000 | ||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | 3,025,000 | $ 3,025,000 | $ 3,025,000 | ||||||||||
Receivable with Imputed Interest, Effective Yield (Interest Rate) | 8% | 8% | |||||||||||
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member] | |||||||||||||
Extinguishment of Debt, Amount | $ 74,647 | $ 74,647 | $ 74,647 |
Note 2 - Going Concern (Details
Note 2 - Going Concern (Details Textual) - USD ($) | 12 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Retained Earnings (Accumulated Deficit), Total | $ (104,580,122) | $ (103,886,232) |
Working Capital (Deficit) | (3,607,638) | (5,054,593) |
Net Cash Provided by (Used in) Operating Activities, Total | (1,866,154) | (2,185,220) |
Cash Provided by (Used in) Operating Activities, Discontinued Operations | (87,772) | (118,644) |
Discontinued Operations [Member] | ||
Working Capital (Deficit) | (1,201,488) | |
Cash Provided by (Used in) Operating Activities, Discontinued Operations | $ (87,772) | $ (118,644) |
Note 3 - Basis of Presentatio_2
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) | 12 Months Ended | |
Mar. 31, 2022 USD ($) shares | Mar. 31, 2021 USD ($) shares | |
Short-Term Investments, Total | $ 0 | $ 0 |
Finite-Lived Intangible Assets, Net, Ending Balance | $ 2,222,074 | 1,706,762 |
Indefinite-Lived Intangible Assets, Pending, Number | 18 | |
Research and Development Expense, Total | $ 821,321 | $ 352,274 |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares | 118,594,624 | 164,049,941 |
Minimum [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 3 years | |
Maximum [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 8 years | |
Licensed Patents [Member] | ||
Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance | $ 928,667 | |
Trademarks [Member] | ||
Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance | $ 15,089 | |
Patents [Member] | ||
Finite-Lived Intangible Assets, Number | 6 | |
Amortization of Intangible Assets | $ 61,105 | $ 34,555 |
Finite-Lived Intangible Assets, Net, Ending Balance | $ 1,278,318 | |
Patents [Member] | GBS Global Biopharma, Inc [Member] | ||
Finite-Lived Intangible Assets, Number | 4 | |
Licensed Patents [Member] | ||
Finite-Lived Intangible Assets, Number | 2 |
Note 4 - Discontinued Operati_3
Note 4 - Discontinued Operations (Details Textual) - USD ($) | 12 Months Ended | 28 Months Ended | |||
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2022 | Dec. 31, 2021 | Nov. 27, 2019 | |
Inventory, Net, Total | $ 0 | ||||
Proceeds from Lines of Credit, Total | $ 0 | 375,000 | |||
Line of Credit [Member] | |||||
Debt Instrument, Interest Rate, Stated Percentage | 8% | ||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 470,000 | ||||
Proceeds from Lines of Credit, Total | $ 485,000 | ||||
Line of Credit Facility, Maximum Borrowing Capacity, Increased | $ 15,000 | ||||
Long-term Line of Credit, Total | $ 485,000 | ||||
Interest Payable | $ 49,211 | ||||
Maximum [Member] | |||||
Lessee, Finance Lease, Discount Rate | 11.50% | 11.50% | |||
Discontinued Operations [Member] | |||||
Accounts Receivable, after Allowance for Credit Loss, Total | $ 0 | $ 0 | |||
Inventory, Net, Total | 1,689,304 | ||||
Deposits Assets, Noncurrent | $ 0 | $ 82,904 | $ 0 |
Note 4 - Discontinued Operati_4
Note 4 - Discontinued Operations - Discontinued Operations (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | |
Cash | $ 233,893 | $ 793,040 | |
Inventory, net | 0 | ||
Prepaid and other current assets | 93,933 | 256,251 | |
TOTAL CURRENT ASSETS | 327,826 | 3,543,855 | |
Property and equipment, net | 0 | 25,022 | |
Finite-Lived Intangible Assets, Net, Ending Balance | 2,222,074 | 1,706,762 | |
TOTAL ASSETS | 2,549,900 | 10,806,054 | |
Accounts payable | 1,657,008 | 1,412,459 | |
Accrued interest | 384,769 | 493,741 | |
Accrued liabilities | 9,627 | 957,946 | |
Indebtedness to related parties | 0 | 84,913 | |
Income tax payable | 896,495 | 761,509 | |
Convertible notes payable, net | 397,308 | 292,410 | |
TOTAL LIABILITIES | 4,332,772 | 12,279,982 | |
Sales revenue | 0 | 0 | |
Cost of goods sold | 0 | 0 | |
Gross profit (loss) | 0 | 0 | |
General and administrative expenses | 1,868,734 | 2,001,617 | |
Gain on extinguishment | 22,405 | 467,872 | |
Gain on settlement of accounts payable | 0 | 422,414 | |
Gain on deconsolidation | $ 5,206,208 | 5,206,208 | 0 |
Interest expense | (474,768) | (1,285,460) | |
Loss on modification of line of credit | 0 | (650,000) | |
Loss on impairment of note receivable | (3,025,000) | 0 | |
Debt default penalty | 0 | (286,059) | |
Loss on disposal | (15,639) | 0 | |
Other income | 9,000 | 0 | |
Total other income/(expense) | 1,722,206 | (1,331,233) | |
Income tax expense (Note 8) | 0 | 0 | |
NET LOSS | (384,345) | (392,177) | |
Continuing Operations [Member] | |||
Cash | 233,893 | 793,040 | |
Prepaid and other current assets | 93,933 | 256,251 | |
TOTAL CURRENT ASSETS | 327,826 | 1,049,291 | |
Property and equipment, net | 25,022 | ||
Finite-Lived Intangible Assets, Net, Ending Balance | 2,222,074 | 1,706,762 | |
TOTAL ASSETS | 2,549,900 | 2,781,075 | |
Accounts payable | 1,657,008 | 1,412,459 | |
Accrued interest | 384,769 | 493,741 | |
Accrued liabilities | 9,627 | 957,946 | |
Notes and convertible notes payable, net | 987,565 | 3,594,804 | |
Indebtedness to related parties | 84,913 | ||
Income tax payable | 896,495 | 761,509 | |
Convertible notes payable, net | 397,308 | 292,410 | |
TOTAL LIABILITIES | 4,332,772 | 7,597,782 | |
Sales revenue | 0 | 0 | |
Cost of goods sold | 0 | 0 | |
Gross profit (loss) | 0 | 0 | |
General and administrative expenses | 1,868,734 | 2,001,617 | |
LOSS FROM OPERATIONS | (1,868,734) | (2,001,617) | |
Gain on extinguishment | 22,405 | 467,872 | |
Gain on settlement of accounts payable | 0 | 422,414 | |
Gain on deconsolidation | 5,206,208 | 0 | |
Interest expense | (474,768) | (1,285,460) | |
Loss on modification of line of credit | 0 | (650,000) | |
Loss on impairment of note receivable | (3,025,000) | 0 | |
Debt default penalty | 0 | (286,059) | |
Loss on disposal | (15,639) | 0 | |
Other income | 9,000 | 0 | |
Total other income/(expense) | 1,722,206 | (1,331,233) | |
NET LOSS BEFORE INCOME TAXES | (146,528) | (3,332,850) | |
Income tax expense (Note 8) | 0 | 0 | |
NET LOSS | (146,528) | (3,332,850) | |
Discontinued Operations [Member] | |||
Cash | 0 | 352,593 | |
Accounts receivable, net | 400,175 | ||
Inventory, net | 1,689,304 | ||
Prepaid and other current assets | 0 | 52,492 | |
TOTAL CURRENT ASSETS | 2,494,564 | ||
Property and equipment, net | 4,876,247 | ||
Finite-Lived Intangible Assets, Net, Ending Balance | 571,264 | ||
Deposits and other noncurrent assets | 0 | 82,904 | |
TOTAL ASSETS | 8,024,979 | ||
Accounts payable | 509,477 | ||
Accrued interest | 49,211 | ||
Accrued liabilities | 105,421 | ||
Notes and convertible notes payable, net | 485,000 | ||
Finance lease obligations, current | 143,967 | ||
Finance lease obligations, long term | 3,389,124 | ||
TOTAL LIABILITIES | 4,682,200 | ||
Sales revenue | 3,369,812 | 4,110,456 | |
Cost of goods sold | (3,072,622) | (3,506,722) | |
Gross profit (loss) | 297,190 | 603,734 | |
General and administrative expenses | 264,515 | 276,986 | |
LOSS FROM OPERATIONS | 32,675 | 326,748 | |
Gain on extinguishment | 0 | 0 | |
Gain on settlement of accounts payable | 0 | 54,958 | |
Gain on deconsolidation | 0 | 0 | |
Interest expense | (302,923) | (486,481) | |
Loss on modification of line of credit | 0 | 0 | |
Loss on impairment of note receivable | 0 | 0 | |
Debt default penalty | 0 | 0 | |
Loss on disposal | 0 | 0 | |
Other income | 20,889 | (118,875) | |
Total other income/(expense) | (282,034) | (550,398) | |
NET LOSS BEFORE INCOME TAXES | (249,359) | (223,650) | |
Income tax expense (Note 8) | (134,986) | (168,527) | |
NET LOSS | (384,345) | (392,177) | |
Segment, Continuing and Discontinued Operations [Member] | |||
Cash | 233,893 | 1,145,633 | |
Accounts receivable, net | 400,175 | ||
Inventory, net | 1,689,304 | ||
Prepaid and other current assets | 93,933 | 308,743 | |
TOTAL CURRENT ASSETS | 327,826 | 3,543,855 | |
Property and equipment, net | 4,901,269 | ||
Finite-Lived Intangible Assets, Net, Ending Balance | 2,222,074 | 2,278,026 | |
Deposits and other noncurrent assets | 82,904 | ||
TOTAL ASSETS | 2,549,900 | 10,806,054 | |
Accounts payable | 1,657,008 | 1,921,936 | |
Accrued interest | 384,769 | 542,952 | |
Accrued liabilities | 9,627 | 1,063,367 | |
Notes and convertible notes payable, net | 987,565 | 4,079,804 | |
Indebtedness to related parties | 84,913 | ||
Income tax payable | 896,495 | 761,509 | |
Finance lease obligations, current | 143,967 | ||
Convertible notes payable, net | 397,308 | 292,410 | |
Finance lease obligations, long term | 3,389,124 | ||
TOTAL LIABILITIES | 4,332,772 | 12,279,982 | |
Sales revenue | 3,369,812 | 4,110,456 | |
Cost of goods sold | (3,072,622) | (3,506,722) | |
Gross profit (loss) | 297,190 | 603,734 | |
General and administrative expenses | 2,133,249 | 2,278,603 | |
LOSS FROM OPERATIONS | (1,836,059) | (1,674,869) | |
Gain on extinguishment | 22,405 | 467,872 | |
Gain on settlement of accounts payable | 0 | 477,372 | |
Gain on deconsolidation | 5,206,208 | 0 | |
Interest expense | (777,691) | (1,771,941) | |
Loss on modification of line of credit | 0 | (650,000) | |
Loss on impairment of note receivable | (3,025,000) | 0 | |
Debt default penalty | 0 | (286,059) | |
Loss on disposal | (15,639) | 0 | |
Other income | 29,889 | (118,875) | |
Total other income/(expense) | 1,440,172 | (1,881,631) | |
NET LOSS BEFORE INCOME TAXES | (395,887) | (3,556,500) | |
Income tax expense (Note 8) | (134,986) | (168,527) | |
NET LOSS | $ (530,873) | $ (3,725,027) |
Note 4 - Discontinued Operati_5
Note 4 - Discontinued Operations - Schedule of Inventory (Details) - USD ($) | Mar. 31, 2022 | Mar. 31, 2021 |
Total inventory (discontinued operations) | $ 0 | |
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | ||
Raw materials | $ 0 | 86,076 |
Work in progress | 0 | 743,844 |
Finished goods | 0 | 866,195 |
Subtotal | 0 | 1,696,115 |
Allowance to reduce inventory to NRV | 0 | (6,811) |
Total inventory (discontinued operations) | $ 0 | $ 1,689,304 |
Note 4 - Discontinued Operati_6
Note 4 - Discontinued Operations - Lease Costs Recorded in the Company's Financial Statements (Details) - Discontinued Operations [Member] - USD ($) | 12 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Finance leases - amortization of ROU assets | $ 116,024 | $ 154,699 |
Finance leases - interest on lease liabilities | 301,796 | 414,993 |
Operating leases | 0 | 3,243 |
Total lease cost, discontinued operations | $ 417,820 | $ 572,935 |
Note 5 - Notes Payable and Li_3
Note 5 - Notes Payable and Line of Credit (Details Textual) | 1 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||
Mar. 04, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 14, 2021 USD ($) | Dec. 29, 2020 USD ($) | Aug. 10, 2020 USD ($) | Oct. 23, 2017 USD ($) | Mar. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2021 USD ($) | Mar. 31, 2022 USD ($) | Mar. 31, 2021 USD ($) | Jul. 24, 2020 USD ($) | |
Gain (Loss) on Extinguishment of Debt, Total | $ 22,405 | $ 467,872 | ||||||||||
Gain (Loss) on Amendment to Line of Credit | 0 | (650,000) | ||||||||||
GB Sciences Nopah, LLC [Member] | ||||||||||||
Receivable with Imputed Interest, Effective Yield (Interest Rate) | 8% | 8% | ||||||||||
Extinguishment of Debt, Amount | $ 3,462,854 | $ 3,462,854 | ||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 3,025,000 | 3,025,000 | 3,025,000 | |||||||||
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member] | ||||||||||||
Extinguishment of Debt, Amount | 74,647 | $ 74,647 | $ 74,647 | |||||||||
Teco Subsidiaries [Member] | The July 24 Note [Member] | ||||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | 1,025,000 | $ 3,025,000 | 1,025,000 | 1,025,000 | ||||||||
Increase (Decrease) in Notes Receivable, Current | 975,000 | |||||||||||
Notes Receivable, Maximum Allowed Prepayments On Note | 325,000 | |||||||||||
Disposal Group, Including Discontinued Operation, Consideration | $ 4,000,000 | |||||||||||
Gain (Loss) on Amendment to Line of Credit | $ (650,000) | |||||||||||
Notes Receivable, Additional Advances | 50,000 | |||||||||||
Interest and Debt Expense, Total | 12,510 | |||||||||||
The July 24 Note [Member] | Revolving Credit Facility [Member] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8% | |||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 500,000 | |||||||||||
The July 24 Note [Member] | Teco Subsidiaries [Member] | ||||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,000,000 | |||||||||||
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding | 3 | |||||||||||
Promissory Note [Member] | ||||||||||||
Debt Instrument, Face Amount | $ 496,797 | 496,797 | ||||||||||
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 0% | 0% | ||||||||||
Debt Instrument, Face Amount | $ 700,000 | |||||||||||
Debt Instrument, Term (Year) | 3 years | |||||||||||
Debt Instrument, Present Value | $ 521,067 | |||||||||||
Receivable with Imputed Interest, Effective Yield (Interest Rate) | 20.30% | |||||||||||
Debt Instrument, Unamortized Discount, Total | $ 178,933 | |||||||||||
Notes Payable, Current, Total | $ 369,445 | $ 369,445 | $ 369,445 | |||||||||
Notes Payable, Principal and Interest | $ 201,532 | |||||||||||
Notes Payable, Principal and Interest, After Modified Terms | 179,127 | |||||||||||
Repayment of Notes Payable | 75,000 | 75,000 | ||||||||||
Debt Instrument, Monthly Payment, Amount | $ 5,000 | |||||||||||
Debt Instrument, Interest Rate, Stated Percentage, After Term Modification | 8% | |||||||||||
Gain (Loss) on Extinguishment of Debt, Total | 22,405 | |||||||||||
Notes Payable, Current and Noncurrent | 104,127 | 104,127 | ||||||||||
Interest Payable | $ 616 | $ 616 | ||||||||||
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Membership Interest Purchase Agreement for Sale of Interest in GB Sciences Nopah, LLC [Member] | ||||||||||||
Debt Instrument, Principal Balance After Reduction Upon Close of Disposition | $ 190,272 | |||||||||||
Nevada Medical Marijuana Production License Agreement [Member] | ||||||||||||
Payments to Acquire License | $ 500,000 | |||||||||||
Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member] | ||||||||||||
Ownership of License | 100% | |||||||||||
Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member] | ||||||||||||
Ownership of License | 100% |
Note 5 - Notes Payable and Li_4
Note 5 - Notes Payable and Line of Credit - Summary of Notes and Convertible Notes Payable (Details) - USD ($) | Mar. 31, 2022 | Mar. 31, 2021 | Oct. 23, 2017 |
Discount, short-term notes payable | $ (99,489) | $ (154,590) | |
Discount, short-term notes payable | (1,765) | (296,504) | |
Promissory Note [Member] | |||
Short-Term Notes Payable | 496,797 | ||
Discount, short-term notes payable | (99,489) | (154,590) | |
Carrying value, long-term notes payable | 397,308 | 292,410 | |
Total short term notes and convertible notes payable classified as continuing operations | 447,000 | ||
Face Value, long-term notes payable | 447,000 | ||
The 0% Note Payable Dated October 23, 2017 [Member] | Note Payable [Member] | |||
Short-Term Notes Payable | 49,797 | ||
Carrying value, long-term notes payable | 49,797 | ||
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member] | |||
Short-Term Notes Payable | $ 700,000 | ||
The 6 % Note Payable Dated September 30, 2023 [Member] | Convertible Debt [Member] | |||
Short-Term Notes Payable | 197,000 | 197,000 | |
Discount, short-term notes payable | (26,254) | (40,561) | |
Carrying value, long-term notes payable | 170,746 | 156,439 | |
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Convertible Debt [Member] | |||
Short-Term Notes Payable | 250,000 | ||
Discount, short-term notes payable | (73,235) | ||
Carrying value, long-term notes payable | 176,765 | ||
The 6 % Note Payable Dated December 31, 2023 [Member] | Convertible Debt [Member] | |||
Short-Term Notes Payable | 250,000 | ||
Discount, short-term notes payable | (114,029) | ||
Carrying value, long-term notes payable | 135,971 | ||
Note Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | |||
Short-Term Notes Payable | 54,330 | ||
Carrying value, short-term notes payable | 54,330 | ||
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | |||
Short-Term Notes Payable | 369,445 | ||
Carrying value, short-term notes payable | 369,445 | ||
Discount, short-term notes payable | 0 | ||
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member] | |||
Short-Term Notes Payable | 560,000 | 1,060,000 | |
Carrying value, short-term notes payable | 560,000 | 1,060,000 | |
Discount, short-term notes payable | 0 | ||
Convertible Notes Payable [Member] | The 6% Notes Payable Due January 18, 2022 [Member] | |||
Short-Term Notes Payable | 325,000 | 325,000 | |
Carrying value, short-term notes payable | 325,000 | 28,496 | |
Discount, short-term notes payable | (296,504) | ||
Convertible Notes Payable [Member] | The 6% Notes Payable Due July 1, 2022 [Member] | |||
Short-Term Notes Payable | 50,000 | ||
Carrying value, short-term notes payable | 48,235 | ||
Discount, short-term notes payable | (1,765) | ||
Line of Credit [Member] | The 8% Line of Credit Dated November 27, 2019 [Member] | |||
Short-Term Notes Payable | 485,000 | ||
Carrying value, short-term notes payable | 485,000 | ||
Discount, short-term notes payable | 0 | ||
Line of Credit [Member] | The 8% Line of Credit Dated July 24, 2020 [Member] | |||
Short-Term Notes Payable | 1,025,000 | ||
Carrying value, short-term notes payable | 1,025,000 | ||
Discount, short-term notes payable | 0 | ||
Promissory Note [Member] | |||
Short-Term Notes Payable | 989,330 | 4,376,308 | |
Carrying value, short-term notes payable | 987,565 | 4,079,804 | |
Discount, short-term notes payable | $ (1,765) | ||
Discount, short-term notes payable | (296,504) | ||
Less: Notes payable classified as discontinued operations, face value | (485,000) | ||
Less: Notes payable classified as discontinued operations, discount | 0 | ||
Less: Notes payable classified as discontinued operations, carrying value | (485,000) | ||
Total short term notes and convertible notes payable classified as continuing operations | 3,891,308 | ||
Total short term notes and convertible notes payable classified as continuing operations | (296,504) | ||
Total short term notes and convertible notes payable classified as continuing operations | 3,594,804 | ||
Face Value, long-term notes payable | 3,891,308 | ||
Senior Secured Convertible Promissory Note [Member] | The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | |||
Short-Term Notes Payable | 1,111,863 | ||
Carrying value, short-term notes payable | 1,111,863 | ||
Discount, short-term notes payable | $ 0 |
Note 6 - Convertible Notes (Det
Note 6 - Convertible Notes (Details Textual) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||||||
Dec. 16, 2020 USD ($) | Jul. 14, 2020 USD ($) | Apr. 22, 2020 USD ($) | Nov. 18, 2019 USD ($) $ / shares shares | Oct. 30, 2019 USD ($) $ / shares shares | Apr. 23, 2019 USD ($) $ / shares | Feb. 28, 2019 USD ($) $ / shares | Jan. 31, 2022 USD ($) | Jul. 31, 2017 USD ($) $ / shares | Mar. 31, 2017 USD ($) $ / shares | Mar. 31, 2021 USD ($) $ / shares shares | May 31, 2017 USD ($) $ / shares shares | Sep. 30, 2020 USD ($) | Dec. 31, 2017 USD ($) $ / shares shares | Dec. 18, 2020 USD ($) $ / shares | Mar. 31, 2022 USD ($) $ / shares shares | Mar. 31, 2021 USD ($) $ / shares shares | Mar. 31, 2020 USD ($) | Dec. 31, 2021 USD ($) Rate | Dec. 09, 2020 USD ($) | Nov. 20, 2020 USD ($) | |
Class of Warrant or Right, Issued During Period (in shares) | shares | 2,095,333 | 43,493,809 | |||||||||||||||||||
Amortization of Debt Discount (Premium) | $ 356,340 | $ 776,122 | |||||||||||||||||||
Debt Default Penalty | 0 | 286,059 | |||||||||||||||||||
Proceeds from Convertible Debt | 50,000 | 725,000 | |||||||||||||||||||
Convertible Notes Payable, Current | $ 3,594,804 | 987,565 | 3,594,804 | ||||||||||||||||||
Debt Instrument, Unamortized Discount, Current | 296,504 | 1,765 | 296,504 | ||||||||||||||||||
Convertible Notes Payable, Noncurrent | 292,410 | 397,308 | 292,410 | ||||||||||||||||||
Debt Instrument, Unamortized Discount, Noncurrent | 154,590 | 99,489 | 154,590 | ||||||||||||||||||
Repayment of Iliad Note [Member] | Judicial Ruling [Member] | |||||||||||||||||||||
Debt Instrument, Debt Default, Interest Rate Penalty | 15% | ||||||||||||||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 3,264,594 | ||||||||||||||||||||
Litigation Settlement, Amount Final Settlement | $ 3,006,015 | $ 3,006,015 | |||||||||||||||||||
Litigation Settlement, One Time Required Payment | 25,000 | ||||||||||||||||||||
Litigation Settlement, Weekly Required Payment | $ 25,000 | ||||||||||||||||||||
Litigation Settlement, Payment | $ 3,006,015 | ||||||||||||||||||||
Discontinued Operations, Disposed of by Sale [Member] | Teco Sale [Member] | |||||||||||||||||||||
Notes and Accrued Interest Payable, Exchange Reduction, Percentage (Rate) | Rate | 110% | ||||||||||||||||||||
Disposal Group, Including Discontinued Operation, Consideration | $ 4,000,000 | ||||||||||||||||||||
Increase (Decrease) Liability Due from Exchange Reduction, Percentage (Rate) | Rate | 10% | ||||||||||||||||||||
Increase (Decrease) Liability Due from Exchange Reduction, Value | $ 125,686 | ||||||||||||||||||||
Convertible Debt [Member] | |||||||||||||||||||||
Debt Instrument, Extended Amount | 197,000 | 197,000 | |||||||||||||||||||
Convertible Notes Payable, Total | 560,000 | ||||||||||||||||||||
Interest Expense, Debt, Total | 286,119 | ||||||||||||||||||||
Interest Payable | 57,846 | ||||||||||||||||||||
Debt Instrument, Debt Default, Amount | $ 1,060,000 | ||||||||||||||||||||
Repayments of Convertible Debt | $ 500,000 | ||||||||||||||||||||
Warrants Issued in March 2017 Convertible Note Offering [Member] | |||||||||||||||||||||
Debt Instrument, Convertible, Number of Warrants | 4,000 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.60 | $ 0.60 | |||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | 3 years | |||||||||||||||||||
Class of Warrant or Right, Issued (in shares) | shares | 8,000,000 | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares | 1 | ||||||||||||||||||||
Warrants Issued In March 2017 and July 2017 Convertible Note Offerings [Member] | |||||||||||||||||||||
Debt Instrument, Convertible, Number of Warrants | 4,000 | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | shares | 788,000 | ||||||||||||||||||||
Warrants Related to July 2017 Convertible Note Offering [Member] | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.65 | $ 0.60 | |||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | ||||||||||||||||||||
Class of Warrant or Right, Issued (in shares) | shares | 28,804,000 | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares | 1 | ||||||||||||||||||||
Warrants Issued in September 30, 2023, Convertible Note Offering [Member] | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.10 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | ||||||||||||||||||||
Warrants and Rights Outstanding | $ 13,396 | ||||||||||||||||||||
March And July 2017 Convertible Note Offering [Member] | Convertible Debt [Member] | |||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | 46,886 | ||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 33,490 | ||||||||||||||||||||
Interest Expense, Debt, Total | 26,127 | ||||||||||||||||||||
Amortization of Debt Discount (Premium) | 14,306 | ||||||||||||||||||||
Interest Payable | 56,152 | ||||||||||||||||||||
Interest Payable, Accrued Prior to Extinguishments | 38,438 | ||||||||||||||||||||
The 6 % Convertible Note Payable Dated December 31, 2023 [Member] | |||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6% | ||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.05 | ||||||||||||||||||||
Interest Expense, Debt, Total | 378,777 | ||||||||||||||||||||
Amortization of Debt Discount (Premium) | 342,033 | ||||||||||||||||||||
Convertible Notes Payable, Current | 373,235 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount, Current | 1,765 | ||||||||||||||||||||
Convertible Notes Payable, Noncurrent | 176,765 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount, Noncurrent | 73,235 | ||||||||||||||||||||
The 6 % Convertible Note Payable Dated December 31, 2023 [Member] | Three Investors [Member] | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 625,000 | ||||||||||||||||||||
The 6 % Convertible Note Payable Mature in December 2021 [Member] | Three Investors [Member] | |||||||||||||||||||||
Debt Instrument, Face Amount | 375,000 | ||||||||||||||||||||
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Three Investors [Member] | |||||||||||||||||||||
Debt Instrument, Face Amount | 250,000 | ||||||||||||||||||||
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Convertible Debt [Member] | |||||||||||||||||||||
Debt Instrument, Face Amount | 250,000 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount, Noncurrent | 73,235 | ||||||||||||||||||||
The 6 Percent Convertible Note Payable Issued With In Money Conversion Features [Member] | |||||||||||||||||||||
Debt Instrument, Face Amount | 425,000 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | 81,250 | 6,500 | |||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 347,000 | ||||||||||||||||||||
Proceeds from Convertible Debt | $ 543,750 | 50,000 | |||||||||||||||||||
Convertible Notes Payable [Member] | |||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 0 | 543,886 | |||||||||||||||||||
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | |||||||||||||||||||||
Debt Instrument, Face Amount Per Note | $ 1,000 | ||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6% | ||||||||||||||||||||
Debt Instrument, Face Amount | $ 2,000,000 | ||||||||||||||||||||
Debt Instrument, Term (Year) | 3 years | ||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ 1,933,693 | ||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 904,690 | ||||||||||||||||||||
Debt Instrument, Convertible, Discount, Fair Value of Warrants | $ 1,029,003 | ||||||||||||||||||||
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | Common Stock [Member] | |||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 4,000 | 8,000,000 | |||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.25 | ||||||||||||||||||||
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | |||||||||||||||||||||
Debt Instrument, Face Amount Per Note | $ 1,000 | ||||||||||||||||||||
Debt Instrument, Face Amount | $ 7,201,000 | ||||||||||||||||||||
Debt Instrument, Term (Year) | 3 years | 3 years | |||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ 7,092,796 | ||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 3,142,605 | ||||||||||||||||||||
Debt Instrument, Convertible, Discount, Fair Value of Warrants | $ 3,950,191 | ||||||||||||||||||||
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | Common Stock [Member] | |||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 4,000 | 28,804,000 | |||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.25 | ||||||||||||||||||||
Convertible Notes Payable [Member] | March And July 2017 Convertible Note Offering [Member] | |||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.10 | ||||||||||||||||||||
Debt Instrument, Extended Amount | $ 197,000 | ||||||||||||||||||||
Convertible Notes Payable, Total | 1,257,000 | ||||||||||||||||||||
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | |||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8% | ||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.0375 | $ 0.06 | $ 0.17 | ||||||||||||||||||
Debt Instrument, Face Amount | $ 2,765,000 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | 265,000 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total | 440,000 | ||||||||||||||||||||
Payments for Brokerage Fees | $ 175,000 | ||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 50,000 | $ 75,000 | $ 125,000 | ||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 1,333,333 | 1,250,000 | |||||||||||||||||||
Induced Conversion of Convertible Debt Expense | $ 64,706 | ||||||||||||||||||||
Debt Instrument, Debt Default, Interest Rate Penalty | 10% | ||||||||||||||||||||
Debt Instrument, Debt Default, Interest Expense | $ 9,559 | ||||||||||||||||||||
Debt Instrument, Debt Default, Principal Expense | $ 276,500 | ||||||||||||||||||||
Debt Instrument, Debt Default, Increase in Principal Amount, Percent | 10% | ||||||||||||||||||||
Debt Default Penalty | $ 286,059 | ||||||||||||||||||||
Promissory Note [Member] | |||||||||||||||||||||
Debt Instrument, Face Amount | 4,376,308 | 989,330 | 4,376,308 | ||||||||||||||||||
Short-term Debt, Total | 4,079,804 | 987,565 | 4,079,804 | ||||||||||||||||||
Debt Instrument, Unamortized Discount, Current | 296,504 | $ 296,504 | |||||||||||||||||||
Debt Instrument, Unamortized Discount, Noncurrent | $ 1,765 | ||||||||||||||||||||
Promissory Note [Member] | July 2017 Convertible Note Offering [Member] | |||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6% | ||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | |||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8% | ||||||||||||||||||||
Debt Instrument, Face Amount | $ 1,500,000 | ||||||||||||||||||||
Interest Payable | 144,994 | ||||||||||||||||||||
Short-term Debt, Total | $ 1,111,863 | ||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 160,000 | ||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | GB Sciences, Nevada, LLC [Member] | Collateral Pledged [Member] | |||||||||||||||||||||
Noncontrolling Interest, Ownership Percentage by Parent | 100% | ||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member] | |||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 8,823,529 | ||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.17 | $ 0.04 | $ 0.04 | ||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 4,000,000 |
Note 7 - Property and Equipme_2
Note 7 - Property and Equipment (Details Textual) - USD ($) | 12 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Depreciation, Total | $ 25,775 | $ 34,654 |
Depreciation, Capitalized to Inventory | 349,015 | 532,785 |
Discontinued Operations [Member] | ||
Depreciation, Total | $ 16,391 | $ 21,855 |
Note 8 - Income Taxes (Details
Note 8 - Income Taxes (Details Textual) - USD ($) | 12 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2018 | |
Effective Income Tax Rate Reconciliation, Percent, Total | 1.80% | (3.60%) | |
Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations | $ 134,986 | $ 168,527 | |
Income Tax Reconciliation, Prior Year Tax Penalties | 207,945 | $ 53,955 | |
Income Tax Reconciliation, Accrued Interest on Prior Year Tax Liabilities | 22,754 | ||
Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount | 178,727 | $ 506,145 | |
Taxes Payable, Current, Total | 896,495 | 592,982 | |
Operating Loss Carryforwards | 51,507,562 | $ 51,063,886 | |
Operating Loss Carryforwards, Subject to Expiration | 34,481,122 | ||
Operating Loss Carryforwards, Not Subject to Expiration | $ 17,026,440 |
Note 8 - Income Taxes - Reconci
Note 8 - Income Taxes - Reconciliation of Effective Income Tax Expense (Benefit) (Details) - USD ($) | 12 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Tax expense/(benefit) computed at U.S. statutory rates | $ 691,042 | $ (697,040) |
IRC Section 280E | 132,063 | 173,045 |
Other permanent items | 5,526 | 14,407 |
Change in valuation allowance | 579,861 | 26,720 |
Adjustments to valuation of deferred tax assets | (1,408,492) | 603,319 |
Tax return true-up | 58,277 | 0 |
Total provision for income taxes | 58,277 | 120,451 |
Penalties and interest on prior year tax liabilities | 76,709 | 48,076 |
Total income tax expense | $ 134,986 | $ 168,527 |
Note 8 - Income Taxes - Deferre
Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) | Mar. 31, 2022 | Mar. 31, 2021 |
Stock based compensation | $ 3,144,084 | $ 3,131,344 |
Net operating loss carryforward | 10,816,588 | 10,460,788 |
Impairment of long-lived assets | 0 | 975,461 |
Depreciation and Amortization expense | (1,369) | (458,938) |
Other temporary items | (209,714) | (220,795) |
Other temporary items | 209,714 | 220,795 |
Total deferred tax assets | 13,749,589 | 14,329,450 |
Less valuation allowance | (13,749,589) | (14,329,450) |
Net deferred tax asset | $ 0 | $ 0 |
Note 9 - Capital Transactions_2
Note 9 - Capital Transactions (Details Textual) - USD ($) | 3 Months Ended | 11 Months Ended | 12 Months Ended | |||||||||||
Mar. 01, 2022 | Jan. 02, 2021 | Dec. 15, 2020 | Dec. 07, 2020 | Nov. 16, 2020 | Mar. 31, 2021 | Mar. 03, 2022 | Mar. 31, 2022 | Mar. 31, 2021 | Jul. 18, 2021 | Feb. 08, 2021 | Jan. 01, 2021 | Mar. 31, 2020 | Feb. 28, 2019 | |
Proceeds from Warrant Exercises | $ 138,728 | $ 1,075,396 | ||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 2,095,333 | 43,493,809 | ||||||||||||
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share) | $ 0.10 | $ 0.10 | ||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 17,333 | |||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 85,843,036 | 75,124,673 | 85,843,036 | 84,538,161 | ||||||||||
Class of Warrant or Right, Expense | $ 60,667 | $ 211,000 | ||||||||||||
Common Stock [Member] | ||||||||||||||
Exercise of Warrants for Stock, Shares (in shares) | 2,095,333 | 35,798,809 | ||||||||||||
Convertible Debt [Member] | ||||||||||||||
Debt Instrument, Extended Amount | $ 197,000 | $ 197,000 | ||||||||||||
Convertible Notes Payable [Member] | March And July 2017 Convertible Note Offering [Member] | ||||||||||||||
Debt Instrument, Extension Period (Year) | 3 years | |||||||||||||
Debt Instrument, Extended Amount | $ 197,000 | |||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.10 | |||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | ||||||||||||||
Debt Conversion, Original Debt, Amount | $ 160,000 | |||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member] | ||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.04 | $ 0.04 | $ 0.17 | |||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 4,000,000 | |||||||||||||
Scientist and Researcher [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 3,500,000 | |||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.05 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value | $ 168,000 | |||||||||||||
Former Director [Member] | ||||||||||||||
Share-based Payment Arrangement, Expense | $ 6,300 | |||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.03 | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 450,000 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period Before Modification, Fair Value | $ 4,950 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period After Modification, Fair Value | $ 11,250 | |||||||||||||
Employees and Directors [Member] | ||||||||||||||
Share-based Payment Arrangement, Expense | 62,000 | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 3,250,000 | |||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.05 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value | 156,000 | |||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ 78,000 | 78,000 | ||||||||||||
Current Employees [Member] | ||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.05 | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 6,050,000 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period Before Modification, Fair Value | $ 199,600 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period After Modification, Fair Value | 250,650 | |||||||||||||
Share-Based Payment Arrangement, Option [Member] | ||||||||||||||
Share-based Payment Arrangement, Expense | $ 51,050 | $ 60,667 | $ 60,667 | $ 436,349 | ||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 17,333 | |||||||||||||
Share-Based Payment Arrangement, Option [Member] | Scientist and Researcher [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) | 10 years | |||||||||||||
Share-Based Payment Arrangement, Option [Member] | Employees and Directors [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) | 10 years | |||||||||||||
Share-Based Payment Arrangement, Option [Member] | Employees and Directors [Member] | Share-Based Payment Arrangement, Tranche One [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage | 33.30% | |||||||||||||
Share-Based Payment Arrangement, Option [Member] | Employees and Directors [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage | 33.30% | |||||||||||||
Share-Based Payment Arrangement, Option [Member] | Employees and Directors [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage | 33.30% | |||||||||||||
Share-Based Payment Arrangement, Nonemployee [Member] | ||||||||||||||
Share-based Payment Arrangement, Expense | $ 28,800 | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 600,000 | 3,500,000 | ||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.05 | $ 0.05 | ||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 5,883,000 | 6,483,000 | 5,883,000 | 2,383,000 | ||||||||||
Minimum [Member] | ||||||||||||||
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share) | $ 0.030 | |||||||||||||
Maximum [Member] | ||||||||||||||
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share) | $ 0.035 | |||||||||||||
Warrants Issued to Investors in Private Placements [Member] | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.10 | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | |||||||||||||
Class of Warrant or Right, Exercises in Period (in shares) | 7,601,813 | 2,095,333 | 35,798,809 | |||||||||||
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share) | $ 0.01 | $ 0.03 | ||||||||||||
Proceeds from Warrant Exercises | $ 76,068 | $ 56,394 | $ 968,023 | |||||||||||
Brokerage Fees for Issuance of Common Stock and Warrants | 6,266 | 107,373 | ||||||||||||
Induced Dividend from Warrant Exercises | 163,017 | $ 1,591,080 | ||||||||||||
Class of Warrant or Right, Exercised During Period, Intrinsic Value | 62,660 | |||||||||||||
Class of Warrant or Right, Issued During Period, Fair Value | $ 100,357 | |||||||||||||
Exercise of Warrants for Stock, Shares (in shares) | 2,088,667 | |||||||||||||
Warrants Issued to Investors in Private Placements [Member] | Minimum [Member] | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.03 | |||||||||||||
Warrants Issued to Investors in Private Placements [Member] | Maximum [Member] | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.05 | |||||||||||||
Warrants Issued to Researcher as Compensation [Member] | ||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||
Warrants and Rights Outstanding, Term (Year) | 10 years | |||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 600,000 | |||||||||||||
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share) | $ 0.05 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share) | $ 0.048 | |||||||||||||
Convertible Warrant [Member] | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.10 | $ 0.10 | ||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 788,000 | |||||||||||||
Class of Warrant or Right, Extension Period of Securities Called by Warrants or Rights (Year) | 3 years | |||||||||||||
Warrants and Rights Outstanding | $ 13,396 | $ 13,396 | ||||||||||||
Employees and Director Warrants [Member] | Employees and Directors [Member] | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.04 | |||||||||||||
Warrants and Rights Outstanding, Term (Year) | 10 years | |||||||||||||
Share-based Payment Arrangement, Expense | $ 133,000 | |||||||||||||
Warrants and Rights Outstanding | $ 133,000 | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 3,500,000 | |||||||||||||
Compensation Warrants Issued to Brokers [Member] | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.01 | |||||||||||||
Warrants and Rights Outstanding | $ 367,196 | $ 135,861 | ||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 9,424,613 | |||||||||||||
Class of Warrant or Right, Expense | $ 231,335 | |||||||||||||
Compensation Warrants Issued to Brokers [Member] | Minimum [Member] | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.25 | |||||||||||||
Compensation Warrants Issued to Brokers [Member] | Maximum [Member] | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1 | |||||||||||||
Replacement Warrants [Member] | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.10 | |||||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | |||||||||||||
Warrants and Rights Outstanding | $ 1,182,920 | |||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 42,705,809 |
Note 9 - Capital Transactions -
Note 9 - Capital Transactions - Warrant Activity (Details) - $ / shares | 12 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Outstanding (in shares) | 85,843,036 | 84,538,161 |
Warrants issued (in shares) | 2,095,333 | 43,493,809 |
Warrants issued, exercise price (in dollars per share) | $ 0.10 | $ 0.10 |
Warrants exercised (in shares) | (9,697,146) | (35,798,809) |
Warrants expired/cancelled (in shares) | (3,116,550) | (6,390,125) |
Outstanding (in shares) | 75,124,673 | 85,843,036 |
Minimum [Member] | ||
Warrants exercised, exercise price (in dollars per share) | $ 0.030 | |
Warrants expired/cancelled, exercise price (in dollars per share) | 0.60 | |
Maximum [Member] | ||
Warrants exercised, exercise price (in dollars per share) | 0.035 | |
Warrants expired/cancelled, exercise price (in dollars per share) | $ 0.90 |
Note 10 - Employee Benefit Pl_3
Note 10 - Employee Benefit Plan (Details Textual) - USD ($) | 11 Months Ended | 12 Months Ended | ||||||
Dec. 15, 2020 | Mar. 03, 2022 | Mar. 31, 2022 | Mar. 31, 2021 | Sep. 17, 2021 | Oct. 25, 2018 | Jun. 30, 2015 | Feb. 06, 2008 | |
Class of Warrant or Right, Expense | $ 60,667 | $ 211,000 | ||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 17,333 | |||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 0 | 0 | ||||||
Restricted Stock [Member] | ||||||||
Share-based Payment Arrangement, Expense | $ 0 | $ 0 | ||||||
Share-Based Payment Arrangement, Option [Member] | ||||||||
Share-based Payment Arrangement, Expense | $ 51,050 | $ 60,667 | 60,667 | $ 436,349 | ||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 17,333 | |||||||
GB Sciences, Inc. 2007 Amended Stock Option Plan [Member] | Restricted Stock [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 4,500,000 | |||||||
The 2014 Equity Compensation Plan [Member] | Share-Based Payment Arrangement, Option [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 8,500,000 | |||||||
GB Sciences, Inc 2018 Stock Plan [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 10,000,000 | |||||||
The 2021 Equity Incentive Plan [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 20,000,000 | 20,000,000 |
Note 10 - Employee Benefit Pl_4
Note 10 - Employee Benefit Plan - Assumptions (Details) - Share-Based Payment Arrangement, Option [Member] | 12 Months Ended |
Mar. 31, 2021 | |
Weighted-average volatility | 127% |
Expected term (in years) (Year) | 10 years |
Risk-free interest rate | 0.93% |
Note 10 - Employee Benefit Pl_5
Note 10 - Employee Benefit Plan - Option Activity (Details) - USD ($) | 12 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2020 | |
Share-Based Payment Arrangement, Employee [Member] | |||
Outstanding, options (in shares) | 17,733,334 | 10,983,334 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 0.11 | $ 0.28 | |
Outstanding, weighted average remaining contractual life (Year) | 5 years 9 months 18 days | 6 years 9 months 18 days | 6 years 7 days |
Outstanding, aggregate intrinsic value | $ 0 | $ 172,000 | $ 0 |
Granted, options (in shares) | 0 | 6,750,000 | |
Granted, weighted average exercise price (in dollars per share) | $ 0.05 | ||
Exercised, options (in shares) | 0 | 0 | |
Exercised, weighted average exercise price (in dollars per share) | |||
Forfeited, options (in shares) | 0 | 0 | |
Forfeited, weighted average exercise price (in dollars per share) | |||
Outstanding, options (in shares) | 17,733,334 | 17,733,334 | 10,983,334 |
Outstanding, weighted average exercise price (in dollars per share) | $ 0.11 | $ 0.11 | $ 0.28 |
Fully vested and expected to vest, options (in shares) | 17,733,334 | ||
Fully vested and expected to vest, weighted average exercise price (in dollars per share) | $ 0.11 | ||
Exercisable, options (in shares) | 15,566,668 | ||
Exercisable, weighted average exercise price (in dollars per share) | $ 0.12 | ||
Share-Based Payment Arrangement, Nonemployee [Member] | |||
Outstanding, options (in shares) | 5,883,000 | 2,383,000 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 0.14 | $ 0.27 | |
Outstanding, weighted average remaining contractual life (Year) | 7 years 3 months 21 days | 8 years 1 month 9 days | 6 years 9 months |
Outstanding, aggregate intrinsic value | $ 0 | $ 0 | |
Granted, options (in shares) | 600,000 | 3,500,000 | |
Granted, weighted average exercise price (in dollars per share) | $ 0.05 | $ 0.05 | |
Exercised, options (in shares) | 0 | 0 | |
Exercised, weighted average exercise price (in dollars per share) | |||
Forfeited, options (in shares) | 0 | 0 | |
Forfeited, weighted average exercise price (in dollars per share) | |||
Outstanding, options (in shares) | 6,483,000 | 5,883,000 | 2,383,000 |
Outstanding, weighted average exercise price (in dollars per share) | $ 0.13 | $ 0.14 | $ 0.27 |
Fully vested and expected to vest, options (in shares) | 6,483,000 | ||
Fully vested and expected to vest, weighted average exercise price (in dollars per share) | $ 0.13 | ||
Exercisable, options (in shares) | 6,483,000 | ||
Exercisable, weighted average exercise price (in dollars per share) | $ 0.13 |
Note 11 - Commitments and Con_2
Note 11 - Commitments and Contingencies (Details Textual) - USD ($) | Dec. 16, 2020 | Sep. 17, 2020 | Jul. 14, 2020 | Apr. 22, 2020 |
Repayment of Iliad Note [Member] | Judicial Ruling [Member] | ||||
Litigation Settlement, Amount Awarded to Other Party | $ 3,264,594 | |||
Litigation Settlement, Payment | $ 3,006,015 | |||
Payment of Services Provided by Contractor [Member] | Pending Litigation [Member] | ||||
Loss Contingency, Damages Sought, Value | $ 73,050 | |||
Payment of Services Provided by Contractor [Member] | Settled Litigation [Member] | ||||
Payments for Legal Settlements | $ 25,000 | |||
Reduction in Cost Basis of Fixed Asset Related to Litigation | $ 48,050 |
Note 12 - Related Party Trans_2
Note 12 - Related Party Transactions (Details Textual) - USD ($) | 12 Months Ended | |||
Jan. 02, 2021 | Nov. 16, 2020 | Mar. 31, 2022 | Mar. 31, 2021 | |
Repayments of Related Party Debt | $ 0 | $ 151,923 | ||
Leslie Bocskor [Member] | ||||
Due to Related Parties, Total | $ 78,245 | |||
Payments for Postemployment Benefits | 6,500 | |||
Salary and Wage, Excluding Cost of Good and Service Sold, Total | 44,192 | |||
Leslie Bocskor [Member] | Unpaid Severance Compensation [Member] | ||||
Related Party Transaction, Expenses from Transactions with Related Party | 20,000 | |||
Related Party Transaction, Amounts of Transaction | $ 84,745 | |||
Ksenia Griswold [Member] | Unpaid Severance Compensation [Member] | ||||
Due to Related Parties, Total | $ 114,159 | |||
Related Party Transaction, Amounts of Transaction | 57,000 | |||
Other Income | $ 57,159 | |||
John Davis [Member] | ||||
Notes Payable, Related Parties, Current | $ 151,923 | |||
Officers and Directors [Member] | ||||
Repayments of Related Party Debt | 84,913 | |||
Due to Related Parties, Total | $ 0 |
Note 13 - Sale of Membership _3
Note 13 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual) | 9 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2021 USD ($) | Dec. 14, 2021 USD ($) | Aug. 10, 2020 USD ($) | Mar. 24, 2020 USD ($) | Nov. 27, 2019 | Oct. 23, 2017 | Dec. 31, 2021 USD ($) | Dec. 31, 2021 USD ($) | Mar. 31, 2022 USD ($) | Mar. 31, 2022 USD ($) | Mar. 31, 2021 USD ($) | |
Notes Reduction | $ 2,612,854 | $ 0 | |||||||||
Proceeds from Divestiture of Interest in Consolidated Subsidiaries | 1,648,772 | 0 | |||||||||
Deconsolidation, Gain (Loss), Amount | $ 5,206,208 | 5,206,208 | $ 0 | ||||||||
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | |||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 0% | 0% | |||||||||
Receivable with Imputed Interest, Effective Yield (Interest Rate) | 20.30% | ||||||||||
GB Sciences Nopah, LLC [Member] | |||||||||||
Sale of Stock, Percentage of Ownership | 100% | ||||||||||
Noncash or Part Noncash Divestiture, Amount of Consideration Received | $ 312,315 | ||||||||||
Nevada Subsidiaries [Member] | |||||||||||
Sale of Stock, Percentage of Ownership | 100% | ||||||||||
Teco Subsidiaries [Member] | |||||||||||
Sale of Stock, Consideration Received on Transaction | $ 8,000,000 | ||||||||||
Notes Receivable, Interest Rate | 8% | ||||||||||
GB Sciences Nopah, LLC [Member] | |||||||||||
Notes Reduction | 237,668 | ||||||||||
Extinguishment of Debt, Amount | $ 3,462,854 | $ 3,462,854 | |||||||||
Sale of Stock, Percentage of Ownership before Transaction | 100% | ||||||||||
Sale of Stock, Percentage of Ownership after Transaction | 0% | ||||||||||
Proceeds from Divestiture of Interest in Consolidated Subsidiaries | 1,648,772 | $ 1,648,772 | |||||||||
Proceeds From Divestiture of Business, Advances Received | $ 400,000 | 400,000 | 400,000 | ||||||||
Financing Receivable, after Allowance for Credit Loss, Total | 3,025,000 | $ 3,025,000 | $ 3,025,000 | ||||||||
Receivable with Imputed Interest, Effective Yield (Interest Rate) | 8% | 8% | |||||||||
Deconsolidation, Gain (Loss), Amount | $ 5,206,208 | ||||||||||
Note Receivable, Interest Only, Monthly | $ 60,500 | ||||||||||
Quarterly Interest Only Payments on Note Receivable, Years | 1 | 1 | |||||||||
Number of Quarterly Principal and Interest Payments on Note Receivable | 7 | 7 | |||||||||
Note Receivable, Quarterly Principal and Interest Installment | $ 201,774 | ||||||||||
Final Payment, Principal and Interest Payments Due on Note Receivable | $ 2,014,225 | 2,014,225 | |||||||||
Asset Impairment Charges, Total | $ 3,025,000 | ||||||||||
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member] | |||||||||||
Extinguishment of Debt, Amount | $ 74,647 | $ 74,647 | $ 74,647 |
Note 13 - Sale of Membership _4
Note 13 - Sale of Membership Interests in Nevada Subsidiaries - Gain on Deconsolidation (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | |
Cash payments received, including advancements of $400,000 | $ 1,648,772 | $ 0 | |
8% Note Receivable due December 31, 2024 | 3,025,000 | 0 | |
Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates | 2,612,854 | 0 | |
Extinguishment of accrued management fees due to purchaser | 850,000 | 0 | |
GAIN ON DECONSOLIDATION | $ 5,206,208 | $ 5,206,208 | $ 0 |
Nevada Subsidiaries [Member] | |||
Cash payments received, including advancements of $400,000 | 1,648,772 | ||
8% Note Receivable due December 31, 2024 | 3,025,000 | ||
Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates | 2,612,854 | ||
Extinguishment of accrued management fees due to purchaser | 850,000 | ||
Total consideration | 8,136,626 | ||
Carrying amount of assets | 7,130,159 | ||
Carrying amount of liabilities | (4,199,741) | ||
Net assets deconsolidated | $ 2,930,418 |
Note 14 - Concentrations (Detai
Note 14 - Concentrations (Details Textual) - USD ($) | Mar. 31, 2022 | Mar. 31, 2021 |
Cash, Uninsured Amount | $ 0 | $ 513,901 |
Note 15 - Subsequent Events (De
Note 15 - Subsequent Events (Details Textual) - USD ($) | May 09, 2022 | Jul. 18, 2021 |
Warrants Issued to Investors in Private Placements [Member] | ||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.10 | |
Warrants and Rights Outstanding, Term (Year) | 3 years | |
Subsequent Event [Member] | ||
Sale of Units, Maximum Units Allowed in Private Placement | $ 565,000 | |
Sale of Unit, Price Per Unit (in dollars per share) | $ 0.03 | |
Subsequent Event [Member] | Warrants Issued to Investors in Private Placements [Member] | ||
Number of Warrant Received, Per Unit (in shares) | 1 | |
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.10 | |
Warrants and Rights Outstanding, Term (Year) | 5 years | |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 4,166,667 | |
Subsequent Event [Member] | Private Placement [Member] | ||
Number of Common Stock Received, Per Unit (in shares) | 1 | |
Proceeds from Issuance of Private Placement | $ 125,000 | |
Stock Issued During Period, Shares, New Issues (in shares) | 4,166,667 |